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Summary 
The unfolded protein response (UPR) plays a significant role in reducing the burden of protein from the 
endoplasmic reticulum (ER) of cells by enhancing the expression of factors which facilitate protein folding, 
such as chaperones and isomerases, while simultaneously reducing translation and initiating ER-
associated degradation pathways. When confronted with adverse conditions in their microenvironment, 
tumor cells need to adapt their proteomes by producing and secreting factors which support their survival 
and growth. This results in the generation of ER stress conditions that leads to activation of the UPR 
pathway. UPR has been linked to almost every type of cancer including grade IV glioma, glioblastoma, a 
devastating disease with patients surviving on average only 15 months after diagnosis. One of the 
reasons for this poor prognosis is the ability of glioblastoma to induce early angiogenesis followed by 
invasion of the normal brain parenchyma. This PhD thesis focuses on understanding how UPR is 
regulated in glioblastoma and how this contributes to tumor angiogenesis. To this end, the UPR pathway 
in glioblastoma cell lines was first characterized using artificial ER stress inducers. As hypoxia is the 
leading physiological inducer of UPR while also regulating the early events of glioblastoma progression, 
the UPR branches that are activated under hypoxia were investigated. PKR-like kinase (PERK), a UPR 
sensor protein which controls the translation machinery of tumor cells under ER stress was examined in 
detail, and it was determined whether this protein is involved in the regulation of expression and secretion 
of any angiogenic proteins in glioblastoma. For this purpose, proteomic analysis of the conditioned media 
of LN308 glioblastoma cells with and without PERK inhibition was performed and PERK-regulated 
secretory factors were identified. Among the hits was Peptidyl-glycine alpha-amidating monooxygenase 
(PAM), a transmembrane protein which plays a role in the rate-limiting final step of the activation of 
various neuropeptides, including the angiogenic peptide adrenomedullin (ADM). PAM was validated as a 
pro-angiogenic factor for glioblastoma, its regulation by hypoxia (HIF1α) was characterized, and the 
importance of PERK kinase activity for the generation of a small soluble cytosolic cleaved product of PAM 
(PAM-sfCD), which has the ability to induce potential gene expression changes favoring glioblastoma 
progression, was shown. PAM was also found to have mesenchymal-subtype specific expression in 
glioblastoma, where AP-1 was found to be the leading transcription factor regulating PAM transcripts. The 
in vivo study in this thesis illustrates the importance of PAM for glioblastoma growth kinetics in an 
orthotopic xenotransplanted mouse model, revealing an increased overall survival of animals upon PAM 
knockdown. Supporting this, clinical data suggest better survival of glioblastoma patients with lower 
expression of PAM. 
Thus, this work reveals the importance of the PERK-mediated expression and post-translational 
modification of PAM for angiogenesis and tumor progression in glioblastoma, introducing the protein as a 
novel anti-angiogenic therapeutic target in this deadly disease.  
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Zusammenfassung 
Die Reaktion auf entfaltete Proteine (engl. Unfolded protein response, UPR) spielt eine bedeutende Rolle 
bei der Verringerung der Proteinausschüttung aus dem endoplasmatischen Retikulum (ER), indem unter 
anderem die Expression von Chaperonen und Isomerasen verstärkt wird, während gleichzeitig die 
Translation reduziert und ER-assoziierte Abbau Wege initiiert werden. 
Aufgrund veränderter Bedingungen in der unmittelbaren Umgebung, passen Tumorzellen ihr Proteom 
durch die Produktion und Sekretion bestimmter Faktoren, die das Überleben und das Wachstum 
unterstützen, an. Hierzu zählt beispielweise die Bildung eines Stresszustands des ER, der zur Aktivierung 
des UPR-Signalwegs führt. Die Aktivierung des UPR lässt sich bei fast jeder Krebsart, einschließlich dem 
Glioblastom, einem Gliom Grad IV, dessen Standardtherapie aus Tumorresektion gefolgt von Chemo- 
und Radiotherapie besteht, finden. Die schlechte Prognose des Glioblastoms lässt sich durch den frühen 
Beginn der Angiogenese, die zur Invasion in das gesunde Gehirnparenchym führt, erklären. 
Die vorliegende Doktorarbeit beschäftigt sich mit der Fragestellung, wie UPR-Aktivierung im Glioblastom 
reguliert wird und diese zur Tumorangiogenese beiträgt. Hierzu wurde zunächst der UPR-Signalweg in 
verschiedenen Glioblastomzelllinien mit ER-Stress induzierenden Reagenzien charakterisiert. Mittels 
Hypoxie, welches zu den stärksten physiologischen UPR-Auslösern zählt und zusätzlich die frühen 
Ereignisse der Glioblastomentwicklung reguliert, wurden die aktivierten UPR-Signalwege identifiziert. In 
diesem Zusammenhang wurde das UPR-Sensorprotein PKR-like Kinase (PERK), welches die Translation 
in Tumorzellen unter ER-Stress steuert, charaktisiert und der Effekt auf die Regulierung eines 
angiogenen Proteins in Glioblastomen untersucht. Um dies herauszufinden, wurde eine Proteomanalyse 
des konditionierten Mediums von LN308-Glioblastomzellen mit bzw. ohne PERK-Inhibierung durchgeführt 
und die von PERK regulierten sekretorische Faktoren identifiziert. Dabei wurde das 
Transmembranprotein Peptidyl-Glycin-alpha-amidierende Monooxygenase (PAM), das eine signifikante 
Rolle im geschwindigkeitsbestimmenden letzten Schritt der Aktivierung von Neuropeptiden und 
Adrenomedullin (ADM) spielt sowie an der Angiogenese beteiligt ist, gefunden. PAM wurde als pro-
angiogener Faktor in Glioblastomen validiert, dessen Regulierung durch Hypoxie (HIF1α) charakterisiert 
und die Bedeutung der PERK-Kinase-Aktivität für die Entstehung eines löslichen Spaltprodukts von PAM 
(PAM-sfCD) im Cytosol gezeigt. PAM-sfCD trägt zu einer Veränderung der Genexpression zugunsten der 
Entwicklung von Glioblastomen bei. Zusätzlich weist PAM eine erhöhte Proteinexpression im 
mesenchymalen Subtyp von Glioblastomen auf, wobei AP-1 der ausschlaggebende Faktor bei der 
Regulierung der Transkription von PAM ist. Eine in vivo Studie veranschaulicht die Bedeutung von PAM 
für das Glioblastomwachstum an Hand eines orthotopisch, xenotransplantierten Mausmodell und zeigt 
ein verlängertes Überleben von Tieren mit PAM-Knockdown. Dies wird von klinischen Daten, welche das 
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verlängerte Überleben von Glioblastompatienten mit niedrigerer PAM Expression in Verbindung bringen, 
unterstützt. 
Die vorliegende Doktorarbeit hebt daher die Bedeutung der PERK-vermittelte Expression und der 
posttranslationalen Modifikation von PAM mit einem Fokus auf die angiogenen Vorteile hinsichtlich der 
Tumorentwicklung, hervor und unterstreicht somit die Relevanz von PAM als anti-angiogenes Ziel für die 
Therapie von Glioblastomen. 
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1. Introduction 
1.1 Tumors of central nervous system (CNS) 
Chronic diseases for example cancer, cardiovascular diseases, etc, are the leading cause of deaths in 
the world leaving cancer as the second biggest reason of deaths worldwide. A new report submitted by 
the global cancer statistics 2018 (GLOBOCAN) estimated 18.1 million new cases of cancer and 9.6 
million cancer-related deaths in the year 2018 worldwide. Out of all cancer-types, central nervous system 
(CNS) tumor accounts for almost 2.5% of the total deaths (Figure 1)
1
. Brain tumors have been classified 
for past centuries on the basis of microscopic evaluation of expression markers and assigned to different 
putative group of origin on the basis of similarities.  
 
Figure 1. Worldwide estimation of number of deaths caused by different types of tumors as a percentage of 
total number of cancer deaths (2018)
2
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This type of classification was based on the cell of origin namely, astrocytes, oligodendrocytes and 
ependymal cells classifying the tumor into astrocytoma, oligoastrocytoma/oligodendroglioma and 
ependymoma by using hematoxylin and eosin staining (H&E staining), immuno-histochemical analysis of 
different biomarkers and characterization of tissue ultrastructures whereas the clinical relevance was 
mostly ignored in the process
3
. These were further classified on the basis of their malignancy. Continuous 
research in the field at genetic level has brought up the significance genetics of tumors hold in the 
process of tumorigenesis. This has led to the recent updates in 2016 of the WHO classification of brain 
tumors published in 2007. This updated classification takes into account the phenotypic and genotypic 
parameters which in turn provide robust diagnostics, increased accuracy of prognosis and treatment 
response, the best example of which is oligoastrocytoma
4,5
. It includes new tumor entities based on both 
histological and molecular parameters. The new classification contain entities like glioblastoma with 
isocitrate dehydrogenase (IDH)-wildtype and glioblastoma with IDH-mutant; diffuse midline glioma with 
H3 K27M-mutation; RELA fusion-positive ependymoma; wingless (WNT)-activated medulloblastoma and 
sonic hedgehog (SHH)-activated medulloblastoma; and embryonal tumor with multilayered rosettes, 
C19MC-altered. Diffuse glioma, medulloblastomas and other embryonal tumors have obtained a major 
restructuring in this updated version. Louis et al (2016) can be referred for a detailed version of the new 
update of the 2007 WHO classification of the brain tumor
4
. The 2016 WHO classification of glioma has 
grouped this tumor type in different categories on the basis of histological-pathological markers together 
with genetic alterations they have. This classification has been quoted with the statement ―genotype 
trumps phenotype‖ which goes in terms with the diagnosis of the tumor type. The major changes to 
glioma (astrocytoma, oligodendroglioma and ependymoma) classification in the new version of WHO 
(2016) has been linked to genetic alterations like 1p/19q co-deletion, IDH mutations, tumor protein 53, 
alpha-thalassemia syndrome gene (ATRX), the gain of 7 and loss of 10q genotype, EGFR amplification 
and mutations, PTEN mutations, BRAF-KIAA fusion genes and BRAF mutations in glial tumors and 
histone H3F3A and HIST1H3B mutations. Table 1 enlists the major changes in the classification of the 
glioma. 
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Genetic aberrations Type of glioma 
Diffuse astrocytic/ 
oligodendroglial tumors  
IDH wild-type, IDH 
mutant 
Glioblastoma  
IDH mutant  
Diffuse astrocytoma  
Anaplastic astrocytoma  
IDH mutant, 1p/19q 
co-deleted  
Oligodendroglioma  
Anaplastic 
Oligodendroglioma 
H3-K27M mutant  Diffuse midline glioma  
MYBL rearrangement  
Well differentiated pediatric 
diffuse glioma  
Ependymomal tumors  
RELA-fusion  
Ependymoma, RELA-fusion 
positive  
YAP1 gene fusions  Ependymoma  
NF2 mutations  
Spinal intramedullary 
ependymal tumours  
Unidentified 
aberrations  
Posterior fossa (PF) 
ependymal tumours  
Other gliomas  
BRAF-V600E 
mutation  
Pilocytic astrocytoma  
Pleomorphic 
xanthoastrocytoma  
TSC1 or TSC2 
mutation  
Subependymal giant-cell 
astrocytoma  
MYB-QK1 gene 
fusions  
Angiocentric glioma  
 
Table 1 Major glioma entities according to 2016 WHO classification of CNS tumors including the major 
genetic alterations they bear. 
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1.2 Glioblastoma 
Glioblastoma are the most common, highly aggressive, grade IV gliomas, of which almost two-third are 
primary in nature thus leaving patients with little or no clinical history. Primary glioblastoma shows a rapid 
development of tumor in course of less than 3 months with highly infiltrative growth and mostly occur in 
older age (>60 years). On the other hand, secondary glioblastoma develop from low-grade gliomas and 
mostly occur in patients with less than 45 years of age. Both the glioblastoma types differ in their genetic 
background, as primary glioblastoma primarily show EGFR amplifications/mutations, homozygous 
deletion of the CDKN2A-p16
INK4α
 and deletion of PTEN, while secondary glioblastoma shows 
alterations/mutations in IDH1/2 or TP53
6
.   
 
1.2.1 Major genetic alterations in glioblastoma 
Tumor Protein 53 (TP53) 
TP53, present on chromosome 17, acts as a major player in the cell cycle, DNA damage response and 
cellular differentiation mechanisms. TP53 arrests the cell cycle and renders cell to apoptosis in case of 
excessive damage to DNA under various stress conditions by regulating the expression of p21. p21 
protein binds to cyclin-dependent kinases (CDKs) and inhibits the cell cycle progression from G1 phase. 
Another protein, MDM2 acts as a negative regulator of TP53 by directly binding to and inhibiting its 
activity, whereas CDKN2A-p14
ARF
 acts as a negative regulator of MDM2 thereby activating TP53. Any 
genetic alterations in this pathway can lead to the inhibition of TP53-mediated restriction of cell cycle 
progression under conditions of oncogenic transformation thereby supporting neoplastic growth
6
. TP53 
mutation is usually found in 90% of IDH mutant cases with no 1p/19q co-deletion, but does not hold 
diagnostic significance as it is found in many different kind of gliomas including glioblastoma, 
medulloblastoma and pediatric gliomas.  
 
EGFR amplifications and mutations 
Even when 40-50% of glioblastoma cases show either mutation or amplification (occurring because of 
chromosome 7 trisomy or polysomy) or both in the EGFR gene specifically EGFRvIII (leading to the 
mutations in the extracellular domain of the protein), no diagnostic or prognostic relevance has been seen 
so far. EGFRvIII acts as a constitutively active protein ensuring continuous signaling through SHC–
GRB2–RAS and class I PI3K supporting tumorigenicity, cell proliferation and resistence to apoptosis
7
. 
Steps are being taken in exploiting the mutated EGFR conditions and many clinical trials are on the run. 
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PTEN mutation 
Phosphatase and Tensin Homolog (PTEN) acts as a tumor suppressor by inactivating PI3K/AKT 
signaling pathway. Mutations in the gene can lead to continuous activation of PI3K/AKT signaling which 
further enhances cellular proliferation and survival while inhibiting apoptosis
6
. PTEN mutation occurs in 
20-30% of glioblastoma cases and is accompanied with 10q loss of heterozygosity inactivating PTEN 
function. This genetic alteration has little diagnostic value and by far no prognostic outcome.  
 
RB or CDKN2A-p16
INK4α
  
Active RB, retinoblastoma protein, attenuates the progression of cycle by directly binding to E2F 
(transcription factor) and inhibiting transcription of growth-promoting genes. Growth-factor signaling leads 
to the expression of cyclins and CDKs which together phosphorylate and inhibit the activity of RB protein. 
This enhances the E2F-mediated expression of genes necessary for mitosis. Moreover, INK4 family 
members, including CDKN2A-p16
INK4α 
acts as positive regulators of RB-mediated inhibition of E2F 
transcription factor by reducing its cyclins-CDKs-mediated inhibitory phosphorylation. Inactivation of RB 
pathway can occur because of mutations in either of the genes; RB (mutations, deletions or promoter 
methylation) or CDKN2A-p16
INK4α 
(homologous deletion or mutation), and is found in almost 75% of all 
primary glioblastoma patients. 
IDH mutations 
IDH mutations have been found in both IDH1 and IDH2 genes and have been constantly used now days 
for diagnostic purposes. It is a somatic, missense and heterozygous mutation that affects codons 132 and 
172 in IDH1 and IDH2 genes respectively. Out of these, around 90% of the cases show IDH1 R132H 
mutations occurring during the start of the tumorigenesis and remains until the end of tumor progression. 
They are more common in grade II-IV diffuse gliomas but are not present in primary brain tumors. The 
mutation in this enzyme leads to alterations in the enzyme activities leading to increased level of 2-
hydroxyglutarate and lower levels of α-ketoglutarate. This has also been correlated with increased 
methylation of CpG islands across the genome including MGMT gene promoter which might be a reason 
of better outcome of IDH mutant gliomas when combined with chemotherapy along with radiotherapy. O-
6-methylguanine-DNA methyltransferase (MGMT) promoter methylation reduces the expression of this 
protein resulting in better outcome from therapies including alkylating agents
8,9
. 
 
1.2.2 Subtype classification of glioblastoma 
The presence of high degree of genomic heterogeneity within glioblastoma patients led the researchers to 
establish The Cancer Genome Atlas consortium (TCGA) wherein around 600 patient-derived tumors were 
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profiled for whole transcriptome expression patterns and classified on the basis of major clusters thus 
obtained with commonly found mutations in TP53, EGFR, IDH1 and PTEN 
10,11
. These clusters include 
proneural (PN), mesenchymal (MES) and classical (CL) subtype of glioblastoma, including abnormalities 
in IDH1, EGFR and NF1 respectively, with mesenchymal subtype having the worst prognosis for all 
glioblastoma patients
12–14
. Also, many studies have concluded and indicated a proneural to mesenchymal 
switch upon application of current therapies as the main reason behind tumor recurrence 
15,16
. Moreover, 
MES subtype of glioblastoma is found associated with microglia/tumor-associated macrophages (TAMs) 
which support the growth and progression of glioblastoma and are responsible for the poor prognosis. 
This MES glioblastoma phenotype is associated with the deactivation of NF-1 expression in glioblastoma 
which was postulated to act on gene expression changes and thus chemotactic towards TAMs and 
microglia
11,16
. Furthermore, a study based on global methylation pattern of glioblastoma has shown a 
distinct glioma-CpG island methylator phenotype (G-CIMP) and has led to the inclusion of three new 
categories while having the other three categories falling into the already existing transcriptome-based 
glioblastoma subtypes
17
. According to this classification, 30-40% of adult/pediatric glioblastoma has 
exclusive mutations in either H3F3A (K27), H3F3A (G34) or IDH1 genes thereby taking them as major 
alteration for the three distinct methylation-based glioblastoma categories. The other three categories in 
this classification includes glioblastoma with PDGFRA mutations (RTK-I; proneural expression signature), 
EGFR mutations (RTK-II; classical expression signature) and NF1 alteration (Mesenchymal expression 
signature)
17,18
. 
 
1.2.3 Current treatment regimes against gliomas 
Normal treatment regime for glioma involves surgical resection of the tumor followed by radiotherapy and 
chemotherapy. Efforts are being made to enhance the overall effect of the current therapies and thus 
overall survival. Research in the field has helped us understand and better target the aggressive disorder. 
Scientists have expanded their knowledge and incites in understanding and exploiting the latest 
technological advances to invent new strategies which includes targeted-gene and small molecule 
inhibitor therapies, and immunotherapies in order to reduce gliomas burden and increase progression-
free survival
19
. One such example of intra-tumoral gene therapy is via retroviral-based gene transfer, 
where cytosine deaminase gene containing reterovirus is directly injected within tumor cells, an effort by 
Tocagen company. The drug converts an extracellular substrate flucytosine to its active agent 5-
flourouracil killing the cancer cell. The drug is going through phase II/III trials in order to analyze its 
efficacy. Multiple pathways which get modulated in gliomas as explained above are being exploited to find 
targeted therapies. Bevacizumab, a homogenized VEGF antibody found suitable for recurrent 
glioblastoma in a study published in 2009 and thus approved by FDA, had no benefits for overall survival 
to patients having newly diagnosed glioblastoma
20–25
. This has led to understand the possibility of new 
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angiogenic pathways in glioblastoma. A sudden boom in the field of immuno-oncology has opened new 
ways to tackle the disease. Immuno-suppression is one of the most prominent features of glioma that has 
been exploited recently in order to curb the disease. Pathways like PI3K mediated activation of 
AKT/mTOR (activated in low grade gliomas) are also being targeted. Everolimus, an inhibitor of mTOR 
has shown promising preliminary results with increased progression-free survival of patients. Immuno-
suppression has been one of the major hallmarks of gliomas
26,27
. Immuno-therapies like, cellular 
therapies, vaccinations and immuno-modulatory therapies targeting immuno-checkpoints are also under 
clinical trials and have shown major advantages to the patients. Adoptive T cell transfer therapy includes 
patients T cell stimulation against patient tumor cells in vitro and transferring them back in the patients to 
target gliomas. One such example of this therapy is upcoming chimeric antigen receptor (CAR) T-cell 
therapy. Vaccination therapies against tumor specific- (TSAs) or tumor associated antigens (TAAs) like 
HER2, TRP2, GP100, MAGE-1, IL13Rα2, AIM-2 and EGFRvIII, are also under clinical trials for validation 
of their use to treat glioma patients
28–31
. 
 
1.3 Unfolded Protein Response 
Every cell tightly regulates the mechanism behind synthesis, proper folding and maturation of polypeptide 
chains. This helps the cell in maintaining intracellular protein homeostasis and also the tissue 
microenvironment. The plasma membrane and secretory proteins constitute upto 42% of the protein load 
within eukaryotic cells that needs to be processed within the endoplasmic reticulum (ER) (the primary site 
of protein synthesis). ER is also important for lipid biosynthesis
32
, Ca2+ handling
33,34
, and intraorganellar 
trafficking
35
. Certain conditions like nutrient deprivation, hypoxia or redox changes within a cell lead to 
imbalance of the proteome of the cell. Such conditions influence the gene expression profile and changes 
the way the new proteome has to be dealt with. Unfolded protein response is one such pathway which 
makes sure that the change in the proteome of the cell does not get affected at the step of synthesis and 
processing of polypeptide chains. Unfolded protein response enhances the protein folding capacity of the 
ER by increasing the expression of chaperones, enzymes for post-translational modifications and ER-
associated degradation (ERAD) pathway proteins
36
. Under acute ER stress conditions, the UPR leads to 
apoptosis
37
. UPR comprises of three effector proteins (Figure 2) residing on the membrane of the ER: the 
serine/threonine-protein kinase/endoribonuclease IRE1 (IRE1α), the protein kinase R-like ER kinase or 
eukaryotic translation initiation factor 2α kinase 3 (PERK/EIF2AK3) and the cyclic AMP-dependent 
transcription factor 6 (ATF6). These effector proteins detect the misfolded protein in the ER lumen and 
mitigate the ER stress by regulating the transcription and translational machinery of the cell through the 
cytosolic domain. IRE1α and ATF6α change the transcriptome of the cell while PERK protein regulates 
the translation initiation. The ER-resident chaperone 78 kDa glucose-regulated protein 
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(GRP78/BIP/HSPA5) binds to the inactive IRE1α, PERK and ATF6 monomeric units under physiological 
conditions. Upon activation of the UPR, GRP78 is displaced by misfolded proteins activating all the three 
effectors
38
. The effector function of the UPR can be both pro-survival or pro-apoptotic depending upon the 
continuity of the ER stress. Diseases like neurodegenerative
39
, inflammation
40
, diabetes
41
, metabolic 
disorders
42
 and cancer
43–45
, are all associated with UPR.  
 
1.3.1 Effectors of the UPR 
IRE1α 
IRE1α is one of the three effector proteins of the UPR. It is a type-I ER membrane protein comprising of 
977 amino acids (aa) with an ER-lumen domain (aa 19-443), a transmembrane domain (aa 444-464) and 
a cytoplasmic tail (465-977; Figure 3A). ER lumenal domain contains MHC-like motif which binds to either 
misfolded proteins or the chaperones present in the ER
46,47
. GRP78 binds to the hydrophobic amino acids 
present in the ER lumenal domain of IRE1α. During accumulation of misfolded proteins, GRP78 switch its 
binding partner from UPR effectors to the misfolded proteins, rendering the UPR effector proteins ready 
to get activated
38
. This interaction causes conformational changes in the cytosolic domain of IRE1α and 
brings its two monomeric units in close proximity. The cytosolic domain of IRE1α contains two enzymatic 
subunits i.e. a kinase domain and an RNase domain. The kinase domain of IRE1α trans-
autophosphorylates itself at serine 724 residue leaving the enzyme in an active state. This also leads to 
the activation of the RNase domain of IRE1α. Activated IRE1α cleaves off the 26 nucleotide intron from 
the XBP1u (X-box binding protein 1-unspliced) mRNA, leaving two arms ready to be ligated by RTCB 
Ligase enzyme generating XBP1s (XBP1 spliced) mRNA
48
. The XBP1s mRNA thus has a frameshift 
which translates to XBP1s transcription factor. XBP1u protein, translated under normal physiological 
condition, regulates the splicing event of XBP1u mRNA to generate XBP1s mRNA and also mediates  
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Figure 2 The unfolded protein response (UPR) pathway. 
The three branches of the UPR get activated upon detection of misfolded proteins in the endoplasmic reticulum. 
PERK activation induces translation inhibition and expression of anti-oxidant genes. IRE1 regulates expression of 
XBP1s transcription factor regulating expression of ERAD pathway proteins. ATF6 on the other hand is localized to 
the nucleus upon UPR induction and cleaved by Golgi-resident SIP and S2P protease enzymes and cleaved 
ATF6(N) acts as a transcription factor responsible for the expression of several UPR genes. All three branches 
regulated proteins at levels of transcription, translation and post-translation in order to reduce ER protein load and 
maintain protein homeostasis.  
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XBP1s protein to degradation machinery
49–51
. Moreover, IRE1α degrades ER-localized mRNAs, 
ribosomal RNAs and microRNAs via its RNase domain. This activity of IRE1α is termed as Regulated 
IRE1-Dependent Decay (RIDD). IRE1α has been shown to preferentially splice XBP1u mRNA under 
dimerized state while oligomerized state is essential for the RIDD activity of IRE1α
52–55
. There are 
literature evidences showing a basal level of RIDD activity of IRE1α under normal physiological condition 
-within a cell whereas the XBP1u mRNA splicing is only active under oligomerized state of IRE1α. IRE1α 
branch cross-talks with the ATF6α via XBP1s transcription factor
56
. XBP1s is involved in the expression of 
protein chaperones like GRP78 and ERAD pathway protein like EDEM1, ERDJ3 and ERDJ4
57–59
. XBP1s 
also increases the expression of proteins playing a role in secretory pathway and lipid biosynthesis
60–63
. 
The phospho-state of IRE1α has been shown to be reversed by two different phosphatase namely PP2A 
and PPM
64,65
. The pro-survival phenotype of IRE1α activation is termed as adaptive ER stress response. 
Under severe stress conditions, IRE1α effector protein activates JNK signaling pathway which leads the 
cell to apoptosis
66
. IRE1α has many interacting partners which modulates its activity depending on the 
physiological state of the cell. 
 
PERK 
PKR-like kinase (PERK) is a type-I transmembrane protein kinase having a lumenal domain, a 
transmembrane domain and a cytosolic kinase domain (Figure 3B). It comprises of 1116 amino acid with 
a total molecular weight of 125 kDa. The lumenal domain of PERK has 20% identity to the lumenal 
domain of IRE1α protein while its cytosolic domain shares 40% similarity to the PKR kinase enzyme
67,68
. 
Like IRE1α, the lumenal domain of PERK is bound to GRP78 under normal physiological conditions. ER 
stress leads to dissociation of GRP78 from the PERK which leads to dimerization and trans-
autophosphorylation of PERK at threonine 980 residue in the kinase domain leading to its activation
68
. 
PERK can be dephosphorylated and inactivated by the enzyme protein-tyrosine phosphatase 1B 
(PTP1B)
69
. Among the protein which can regulate the inhibition of PERK are DNAJ homolog subfamily C 
member 3 (DNAJC3/P58IPK), which is a member of the HSP40 family and Nck1
70–72
. Active PERK 
phosphorylates its downstream target eIF2α at serine 51 residue blocking the first step of translation 
initiation
73
. eIF2α is a component of EIF2 heterotrimeric complex (subunits α, β, γ; genes:EIF2B1, 
EIF2B2, and EIF2B3). This complex regulates the initial step of translation where methionyl-tRNA binds 
to the ribosome in an αGTP-dependent manner. The phosphorylation of eIF2α increases its affinity 
towards eIF2B which follows the inhibition of the exchange of GDP to GTP thereby leading to translation 
inhibition
74
. But there are certain UPR target mRNAs which are still translated like ATF4
75
, the basic 
zipper transcriptional regulator ATF5
76
, pro-apoptotic protein CHOP
77
, and GADD34
78
 due to the 
presence of upstream open reading frames at the 5’untranslated region (5’UTR). ATF4 is a transcriptional 
factor regulating pro-survival genes like ATF3 during early ER stress as well as the pro-apoptotic gene 
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CHOP under continuous UPR activation. Effect of PERK on eIF2α can be reversed by two ER stress 
regulated proteins namely GADD34 (PPP1R15A) and the constitutively expressed CReP (PPP1R15B) by 
negatively regulating the eIF2α phosphorylation status. eIF2α can also be phosphorylated at serine 51 
residue by three other kinases depending upon the stress conditions a cell is confronting. 
These are GCN2 activated under amino acid starvation, PKR activated under viral infection, and Heme-
regulated inhibitor (HRI) activated under heme-deprivation, and oxidative stress conditions
79
. Nuclear 
factor erythroid 2-related factor 2 (NRF2) was found to be another very important transcription factor 
being activated by PERK. NRF2 acts as a master regulator of redox homeostasis within a cell. It 
transcribes anti-oxidant genes (e.g. glutamate-cysteine ligase catalytic subunit (GCLC), hemeoxygenase-
1) in order to reduce the damaging effect of reactive oxygen species within a cell. PERK-mediated 
phosphorylation of NRF2 leads to disruption of NRF2-KeapN1 interaction and NRF2 nuclear localization 
which otherwise leads to degradation of this transcription factor
80–82
. PERK also phosphorylates and 
induce nuclear localization of FOXO1 transcription factor. PERK-mediated phosphorylation of lipid 
diacylglycerol (DAG), an important second messenger and also precursor for phosphatidic acid (PA), 
regulates the activation of Akt and ERK1/2 signaling downstream of RAS. This triggers activation of the 
mTOR signaling and supports tumorigenesis
83
. 
 
ATF6 
ATF6α/β is the third effector branch of the UPR which does not require any transcription or translation 
step to get activated. It is a type-II transmembrane protein having a C-terminus ER luminal domain, a 
transmembrane domain and an N-terminus cytosolic domain (Figure 3C). The ER-lumen domain contains 
a Golgi translocation signal (GLS). Both the isoforms differs with respect to their function in the UPR 
signaling. The ATF6α isoform acts a transcriptional activator with two GLS on the N-terminus, whereas 
ATF6β acts as a transcriptional repressor protein with only one GLS on the N-terminus
84
. Thus the activity 
of ATF6α depends on the amount of ATF6β expressed within a cell
85
. The cytosolic domain of ATF6α 
contains the basic leucine zipper domain (bZIP) relevant for the transcriptional signaling of the UPR
86
. 
Under normal physiological conditions, both the isoforms can make homo or heteromers of their mono-, 
di- or oligomer units with di-sulphide bridges on their cytosolic domains. It is only under UPR activation 
that GRP78 is displaced from their GLS domain on the ER-lumen side which is now available to 
translocate ATF6 to the golgi vesicle
87
. Several factors have been shown to influence the activation of 
ATF6α/β. Higa and coworkers reported protein disulfide-isomerase A5 (PDIA5) to regulate translocation 
and transcriptional activity of ATF6α/β  which might be a reason for chemotherapy resistance to Imatinib 
in patient-derived leukemia cells
88
. Calreticulin, a co-chaperone was also found bound to the GLS domain 
of the ATF6α/β. Thrombospondin-4 (THBS4) also binds to the ER-lumenal domain of ATF6α/β inducing 
its pro-survival signaling
89
. ATF6α/β  was also shown to be influenced by the dual specificity mitogen-
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activated protein kinase kinase 6 (MAPKK6)- mitogen-activated protein kinase P38 α/β (P38α/β)- pathway 
in dormant human squamous carcinoma cells
90
. The exposure of the GLS domain directs ATF6α/β 
packaging into the COPII vesicles
91
. Wolfram syndrome 1 (WFS1), a responder of the IRE1α branch, can 
influence this process and retain ATF6 in the ER
92
. The two Golgi membrane residing serine protease 
enzymes; membrane-bound transcription factor site-1 protease (S1P) and membrane-bound transcription 
factor site-2 protease (S2P) cleaves ATF6α/β intra-membranously, thereby releasing a 50 kDa fragment 
(ATF6α/β-f), containing the bZIP motive
93
.  This step is of vital importance for the activation and 
transcription activity of ATF6α. The ATF6α/β-f thus generated translocates into the nucleus where it binds 
to the ER stress response element (ERSE) in tandem with nuclear transcription factor Y (NF-Y)
94,95
. The 
ATF6α/β-f can also be subjected to ubiquitination and subsequent proteasomal degradation limiting its 
activity in the UPR
96
. The ATF6α/β-f transcription factor binds not only to the NF-Y but also with XBP1s, 
transcriptional repressor protein YY1 (YY1), and TATA-binding protein which regulates the expression of 
various target genes like XBP1, NF-Y, interleukin-10 (IL-10), as well as its own ATF6α  and ATF6β
97–99
. 
The ATF6/XBP1s heterodimer transcribes the growth arrest and DNA damage inducible 45a (GADD45A) 
inhibiting S-phase transition of the cell cycle and stimulating DNA excision repair
100
. ATF6 also increases 
the expression of DNAJ homolog subfamily C member 3 (DNAJC3/P58IPK) which binds to and inhibits 
the kinase domain of PERK. ATF6 increases the expression of enzymes essential for the post-
translational modifications of newly synthesized polypeptide chains like Protein disulfide- isomerase A4 
(PDIA4) and ERO1. It also leads to the enhancement in the expression of the chaperones GRP78, 
GRP94, Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 
protein (HERPUD1), Calreticulin 2 (CRT2), and Hypoxia up-regulated protein 1(HYOU1) which are all 
essential for maintaining protein homeostasis. In addition, ATF6α also increases ERAD pathway proteins 
OS9, and SEL1 pro-apoptotic proteins CHOP and BCL-2, as well as the sarcoplasmic/endoplasmic 
reticulum calcium ATPase2 (SERCA2) and GTP-binding protein RHEB (Ras homolog enriched in 
brain)
101–104
. 
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Figure 3. Structure of UPR sensor proteins
105
.  
SS (signal peptide), TMD (transmembrane domain), S1P-S2P (cleavage site) 
 
1.3.2 Hypoxia-mediated UPR activation 
Extreme heterogenic nature of the tumor microenvironment in terms of nutrient supply, oxygen and pH 
alters the metabolic and proliferative status of the tumors. Indeed, tumor microenvironment has been a 
major contributor of changes in gene expression leading to aggressive tumor phenotypes including 
proliferation, angiogenesis, metastasis and chemoresistance. Hypoxia, one of the most influencing 
microenvironment conditions within tumor alters the gene expression and cellular functions mostly 
through stabilization of hypoxia-inducible factor HIF1α. The other pathways known to be regulated by 
hypoxia are mTOR signaling and unfolded protein response (Figure 4). Hypoxia leads to the inhibition of 
mTOR signaling reducing phosphorylation of 4EBP1 and thereby inhibiting translation 
106
. It does this by 
activating tuberous sclerosis protein complex (TSC1–TSC2) through different mechanism or via the 
promyelocytic leukaemia tumour suppressor (PML) which binds to and inactivate mTOR by sequestering 
it within nuclear bodies. Although, this can be reversed in advanced stage tumors bearing mutation or 
loss of function in TSC2 and PTEN genes where tumor cells can benefit from active protein translation, 
pro-survival autophagy, energy metabolism and apoptosis inhibition
106–109
. One such example is the 
hypoxia-induced inhibition of mTORC1 in immortalized breast epithelial cells whereas continuous 
activation of mTORC1 in cells derived from advanced stage breast cancer samples under similar 
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conditions
110
. On the other hand, UPR helps tumor cells in adapting to increased ER stress due to 
changes in different signaling pathways during tumorigenesis. It enhances the protein folding capacity of 
the ER and thus contributes to the different phenotypic changes a cancer cell bears under hypoxia like 
angiogenesis and invasion, among others. All the three pathways cross-talk between each other in order 
to regulate cellular metabolism, autophagy, ER stress and thus supporting tumor growth under harsh 
hypoxic conditions
106
. 
 
 
 
Figure 4. Hypoxia-regulated pathways. 
In normal cells, induction of hypoxia leads to activation of UPR, stabilization of HIF1α protein and inhibition of mTOR 
kinase signaling. Tumor cells with mutation in the pathways necessary for inhibiting mTORC1 signaling gather pro-
survival benefits from the mTORC1-mediated translation, energy metabolism and autophagy regulation. UPR 
increases the protein folding capacity of the cell while HIF1α leads to expression of factors necessary of 
angiogenesis, invasion and other hallmarks of cancer. 
 
Hypoxia
Hypoxia-induced gene 
expression
Transcription 
FactorNucleusCytoplasm
PERK
IRE1α
ATF6α
mTORC1
S6K 4EBP1
Protein Synthesis
HIF1α
Induction of UPR Stabilization of HIF1α Inhibition of mTORC1
ER
UPR-mediated expression of 
genes, translation inhibition 
and autophagy induction
INTRODUCTION 
 
15 
  
1.3.3 UPR and Diseases  
UPR has been found active in several health disorders related to the central nervous system (CNS), lung, 
kidney, heart and liver diseases, aging, cancer and metabolic disorders like diabetes, having both 
protective or deteriorating role depending upon the extent of its activation 
111,112,121–124,113–120
. UPR 
activation has been linked to different outcomes in neurodegenerative disorders. For example IRE1/XBP1 
has been found active and responsible for deleterious effects in Epilepsy, amyotrophic lateral sclerosis 
(ALS), and Huntington’s disease, whereas in acute neuronal injury like spinal cord lesions, XBP1s protein 
administration locally enhanced the survival of the cells 
125–129
.  Similar phenomenon was seen in 
Alzheimer’s disease where XBP1 activation decreased amyloid-β accumulation and improved neuronal 
function.
130
 Interestingly, in Parkinson’s disease model, XBP1 deletion gives different phenotypic outcome 
at different stage of the disease
131
. The PERK branch of UPR enhances neuro-protection in Parkinson’s 
and ALS disease by P-eIF2α-mediated translation halt 
132–134
, although reduction in PERK–mediated 
increase in P-eIF2α  improved memory and synaptic functions in case of Alzheimer’s and prion-diseases 
respectively 
135–137
. In diabetes, inactive IRE1 and PERK branch has been found responsible for altered 
insulin secretion, less β-cell viability and increased resistance to insulin during diabetes due to 
accumulation of misfolded insulin and lipotoxicity during the disease 
138–142
. XBP1s mediates expression 
of VEGFα, ATF6α reduces the oxidative stress, ischemia and reperfusion injuries in cardiomyocytes, 
thereby playing a significant role in restoring heart functioning
143–146,147
. PERK normally stays inactive 
possibly to maintain low level of ER stress in injured heart
148
.   
 
1.3.4 UPR in cancer 
UPR activation has been related with almost every stage of a tumor progression, including transformation 
and proliferation of cells, angiogenesis, invasion and tumor metastasis. Cancerous transformation of cells 
requires activation or inactivation of oncogenes and tumor-suppressor genes like BRAFv600E, c-MYC 
and H-RAS, or p53, respectively. This leads to an increased proliferation which further enhances the 
burden on the ER of the cell leading to UPR activation
149–151
. On the other hand, cancer cells try to 
circumvent the potential apoptosis which comes along with the UPR activation by reducing the expression 
of apoptotic protein, for example, H-RAS decreases CHOP mRNA levels in order to reduce the apoptotic 
signaling in mouse embryonic fibroblasts (MEFs)
151
. Active c-MYC was also shown to reduce apoptosis 
by inducing PERK-mediated autophagy
150
. P58IPK, responsible for reducing PERK and PKR activation 
has been implicated in reducing UPR-mediated cell death
70
. This whole process is effective in selecting 
those transformed cells which have optimum ER stress required for pro-survival or adaptive UPR 
response supporting growth and proliferation of cancer cells and circumventing the apoptotic signaling. 
Different branches of UPR have shown differential functioning in regard to proliferation. IRE1-XBP1s 
INTRODUCTION 
 
16 
  
branch has been linked with G1 arrest, whereas PERK activation showed reduction in β-catenin-mediated 
cyclinD1 expression reducing proliferation of the cancer cells
152–154
. UPR activation has many benefits 
under stress like hypoxia and nutrient deprivation. IRE1α-XBP1s axis enhances cell survival under 
hypoxic conditions. In certain cancer types like breast cancer, XBP1s has been found to interact with 
HIF1α and thus increase its transcription efficiency
155
. PERK branch induces autophagy via eIF2α-ATF4 
signaling under hypoxia enabling cancer cells to self sustain under condition of nutrient deprivation
156
. 
Activation of ER stress in cancer cells also changes the secretome and several of these soluble factors 
can induce ER stress in immune system of the host, known as Transmissible ER stress (TRES). In a 
study, TRES has been shown to induce expression of cytokines in dendritic cells providing pro-survival 
benefits to tumor cells both in vitro and in vivo
157,158
. Another study showed reduced expression of MHC 
class I and Natural killer cell-activating receptor ligands MICA/B, due to UPR signaling which thus 
reduced CD8+ T cell and NK cell-mediated cytoxicity
159–161
. Another very important hallmark of cancer, 
i.e. angiogenesis, has also been found regulated by the UPR pathway. All three effector proteins of the 
UPR (IRE1α, PERK, ATF6α) has been shown in different studies regulating angiogenic factors like 
VEGF-A. XBP1s was found directly interacting with HIF1α to enhance its DNA-binding efficiency in triple-
negative breast cancer
155
. PERK also regulates VEGF-A, IL6 and FGF expression via ATF4 transcription 
factor and ATF6α was also found binding to VEGF-A promoter region regulating its expression
162–164
. 
UPR signaling influences the transition of cancer cells under stress from epithelial to mesenchymal 
phenotype both directly and indirectly. IRE1α signaling via XBP1s was shown regulating the expression of 
transcription factors necessary for migration and invasion of cancer cells like Snail1, Snail2, Zeb2 and 
TCF3 transcription factors
165
. One study found a strong association between EMT markers and ATF4 
expression in 792 breast, colon and gastric tumours
166
. Cancer stem-like cells (CSCs) are a sub-
population within tumor which bear the ability to self-renew and also give rise to all different kind of cells 
of the tumor bulk. Moreover, they carry the potency to withstand the cancer therapeutic stress and, 
enhance tumor progression and metastasis. UPR signaling has also been implicated in providing 
resistance to current chemotherapies, which might acts as a process of selecting the most aggressive but 
chemo-resistant cancer–stem cells (Figure 5)
153,155,167
.  
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Figure 5. Role of UPR during different stages of tumor development. 
UPR activation contributes to tumor progression at almost every stage. This happens due to the fact that every stage 
during tumor development brings forward a change in the gene expression profile of the cancer cell, putting forward 
new challenges for the protein folding machinery. In order to maintain protein homeostasis, cancer cell balances the 
optimum activation of all three branches of the UPR and gain from the pro-survival benefits. 
 
1.4 Hallmarks of Cancer 
Tumorigenesis is a multistep process where normal cells evolve to transform into a neoplastic growth by 
successively acquiring different hallmarks of cancer. These hallmarks, as described by Hanahan and 
Weinberg et al (2000), includes sustained proliferative signaling, evasion of growth suppressors, 
induction of angiogenesis, activation of invasion and metastasis, replicative immortality, and resistance 
to cell death168. The revised version of cancer hallmarks, published in 2011 introduced two new 
characteristic traits to this list; reprogramming cellular metabolism to support continuous proliferation 
and growth, and avoidance of immune destruction. They also brought in two major characteristics that 
are responsible for the acquisition of these traits. These characteristics include genomic instability 
(involving both genetic mutations as well as chromosome rearrangements) and inflammatory state of 
the neoplastic tissue where certain immune cell tends to support malignant nature of the tumor169. 
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Tumor mass not just includes cancer cells but also normal cells which are recruited and reprogrammed 
to support tumor cells in attaining these key hallmarks of cancer, including angiogenesis. 
 
1.4.1 Angiogenesis: A major hallmark of glioblastoma 
Angiogenesis is the sprouting of new blood vessels from the existing ones. As the tumor grows, it 
requires constant nutrient and oxygen supply for its well being. This enforces tumor to attain an 
angiogenic switch whereby it regulates the formation of neo-vasculature in its surrounding
170
. 
Glioblastoma achieves this by maintaining a balance between the secretion of pro- and anti-angiogenic 
factors, like VEGF-A and TSP-1, respectively 
171
, where even the tumor stromal cells play significant 
role.
172,173
 Few of the angiogenic inducers in glioblastoma include YKL-40 (chitinase 3 like 1, CHI3L1), a 
glycoprotein which induces the expression of VEGFA via Syndecan-1 (Syn-1) and integrin αvβ5-induced 
activation of focal adhesion kinase (FAK) and extracellular-regulated kinase (ERK) signaling pathways
174
. 
CD147 (Cluster of differentiation 147) is one of the other proangiogenic factors which can induce neo-
vasculature formation via both insulin-like growth factor 1 (IGF-1) and HIF1α.
175,176
 On the other hand, 
LRRC4 (Leucine-rich repeat C4) inhibits the induction of angiogenesis by reducing VEGFA expression 
thereby acting as an anti-angiogenic factor in glioblastoma
177
. Advances in the understanding of the role 
of microRNAs have revealed their significant influence in regulating angiogenesis in glioblastoma. Studies 
have found overexpression of miR-210-3p, miR-21 and miR-296 microRNAs as a favorable event for neo-
blood vessel formation while overexpression of miR-15b and miR-299 has been evidenced as anti-
angiogenic in glioblastoma
178
. VEGF-A ligands (regulated by both hypoxia and Oncogenic signaling) 
binds to VEGF (1-3) receptors present on endothelial cell surface in order to activate endothelial cell 
proliferation and migration towards the tumor 
179,180
. The neo-vasculature thus formed, shows prematurely 
developed capillary sprouting, tangled vessel branching, twisted and out of shape vessels and uneven 
blood circulation 
181
. Angiogenic phenomenon is an early event during premalignant neoplastic growth 
which also supports the invasive phenotype of glioblastoma
182
. Glioblastoma stem-like cells (GSCs), 
which contribute to the tumor heterogeneity and also the reason of chemo-resistance, are equipped with 
the ability to differentiate into endothelial and pericyte-like cells forming a pseudo-vasculature, a 
phenomenon known as ―vasculature mimicry‖.
183–186
 It was found that these endothelial-like tumor cells 
bear similar mutations as is found in the adjacent tumor bulk surrounding the vasculature and was more 
prevalent in the tumor core rather than the tumor edges. Furthermore, immune system of the host also 
plays significant role in enhancing nutrient supply to the growing glioblastoma via induction of 
angiogenesis. The fact that the immune cell infiltration to the tumor microenvironment depends on the 
vessel normalization, application of anti-angiogenic therapies modulate this aspect of tumor vasculature 
leading to recruitment of bone-marrow derived myeloid cells whereas the tumor and stromal secreted 
factors changes the phenotypes of these cells to more tumor–supportive (for example M2 phenotype of 
macrophages) leading to resistence against current anti-angiogenic therapies
187
. These secretory factors 
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include VEGF which suppresses T-cell immune response by inhibiting dendritic cell maturation, 
granulocyte colony-stimulating factor (G-CSF) and interleukin-17 (IL-17) promoting refractoriness of 
glioblastoma to anti-angiogenic therapies
188–190
. Such a complex regulation of angiogenesis requires 
proper stratification of patient cohorts in order to effectively examine the effect of anti-angiogenic 
therapies targeting various angiogenic factors in glioblastoma. Thus there is an urge for a better 
understanding and identification of reliable biomarkers of angiogenesis in glioblastoma. Some of the 
biomarkers that have been taken into consideration are tissue biomarkers including, VEGF, CA9, CD68 & 
CD11 (tumor-associated macrophages); blood biomarkers like VEGF and sVEGFR2, SDF-1α, PIGF, and 
MMPs, and imaging biomarkers
187
. 
 
1.5 Peptidyl-glycine alpha-amidating monooxygenase 
Peptidyl-glycine alpha-amidating monooxygenase (PAM) is the only bi-functional enzyme which activates 
neuro-peptides. PAM, a type-I integral membrane protein, catalyzes the amidation of the C-terminus 
glycine residue with its hydroxylating monooxygenase domain (PHM) which is then identified and cleaved 
off by its lyase enzymatic domain (PAL) in a ascorbate, copper and oxygen dependent manner (Figure 
6)
191–194
. Both the hydroxylating monooxygenase and lyase domain has optimum activity under low pH of 
the secretory pathway lumen
195
. PHM domain is made up of two core domains each having eight anti-
parallel β-strands having hydrophobic core joined by disulphide linkages. Both the domains are linked 
with a single polypeptide chain and each has a copper binding site separated by an 11 A° cleft, a site 
where peptidyl-glycine substrate binds
196,197
. On the other hand, PAL catalytic domain has a six-bladed β-
propeller also held together by disulphide linkages. The cavity in the center of the domain has a calcium 
binding site for structural integrity and a zinc-binding site for catalytic function of the domain
198
.  
 
Figure 6. PAM catalyzes the activation of neuropeptides. 
PHM domain of PAM hydroxylates the c-terminus glycine residue which is then identified and cleaved off by PAL 
domain leading to activation of the neuropeptides, for example, ADM
199
.  
 
The longest isoform of PAM i.e. PAM-1 consists of the two enzymatic domains having endoprotease-
sensitve linker region between them, the transmembrane domain and the cytosolic domain. PAM-2 
isoform lacks this linker region while PAM-3 isoform lack both the transmembrane domain, in addition to 
the linker region between the enzymatic domains and thus is expressed as a soluble isoform (Figure 7).  
-Glycine -α-Hydroxyl-Glycine -NH2
PHM PAL
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Figure 7. PAM splice variants. 
PAM consists of a hydroxylating domain (PHM), a lyse domain (PAL), a linker region between these catalytic domain, 
a transmembrane domain and a cytoplasmic unstructured tail. The figure shows different isoforms of PAM depending 
upon presence and absence of linker region between the catalytic domains and the transmembrane domain of 
PAM
199
. 
 
PAM is expressed in different tissues at varied levels and has been found in endocrine tissues, airway 
epithelium, ependymal cells in the brain, endothelial cells, and adult atrium as well as the brain and 
pituitary. Heart and neuronal tissues have specifically shown tissue-specific expression of different 
isoforms of PAM indicating their distinct roles
200,201
. Soluble forms of PAM have also been found in serum 
and cerebrospinal fluid
202,203
. Apart from the catalytic domains of PAM, another very significant 
component of PAM is the unstructured cytosolic domain (86 amino acids long) sensitive to endo-
proteolytic cleavage. This domain contains few hydrophobic patches and is essential for interaction with 
different proteins including kinases that phosphorylates and regulates PAM trafficking through the 
secretory pathway
204
. KALIRIN and TRIO (Rho GDP/GTP exchange factor (Rho-GEF) family) which are 
essential for cytoskeleton control and the maintenance of synapses, and Rassf9, a member of the Ras-
association domain family (important for epidermal homeostasis) have been found interacting with PAM. 
A  Ser/Thr kinase, Uhmk1, phosphorylates the C-terminus of PAM
205,206
. Adaptor protein-1 (member of 
endosomal and secretory granule coat prtoeins) responsible for linking cargo proteins to clathrin, interacts 
with PAM along with Atp7a (the P-type ATPase necessary for copper transport to golgi-vesicle)
207
. 
Various phosphorylation sites have been detected in the cytosolic domain of PAM using mass 
spectrometry and assigned specific roles in its trafficking through the secretory and endocytic pathway 
using phosphomimetic mutants
204
. The cytosolic domain of PAM can be cleaved off by different enzymes 
like γ-secretase which generates a short-lived 16 kDa soluble protein fragment (sf-CD) also shown to 
localize to the nucleus and act as a signaling molecule
208
. Increased expression of PAM-1 changes the 
cell morphology and modulates expression of certain proteins like copper chaperones, aquaproin 1 and 
Slpi protease inhibitor which might be due to the sf-CD-mediated alteration of gene expression
209
. PAM 
PAL
TMD 
PHM
PAL
TMD 
PHM
Cytosol
Lumen
PAM-1 PAM-2 PAM-3
PAM-CD
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has been correlated with maintenance of copper homeostasis and termed as a copper sensing protein. 
Studies involving PAM heterozygous mice show defects like increased adiposity, behavioral defects like 
body temperature disbalance, increased anxiety and seizures as observed in copper restricted diet in 
normal mice
210–212
. PAM has also been implicated as a rapid sensor of oxygen availability as the PHM 
activity is completely dependent on the presence of oxygen
213
. On the other hand the linker region 
between the PHM and PAL domain of PAM with a cluster of histidine residues (His–Gly–His–His), has 
been shown to act as a pH sensor determining the fate of PAM-1 after being internalized from plasma 
membrane
214
. PAM is expressed in many different cancer types like prostrate, breast, glioblastoma, lung, 
pituitary and colon cancer, and relates with the phenotypic changes brought forward by the downstream 
activated neuropeptides like adrenomedullin
215–222
. Knowing the numerous other functions of PAM 
protein, it will be quiet essential to understand different mechanism with which PAM regulates phenotypic 
changes in cancer in general (Figure 8). 
 
Figure 8. PAM trafficking through biosynthetic and endocytic pathways. 
PAM isoforms are effectively secreted or expressed on the surface of the cell. Post-translational modification of the 
cytosolic domain of PAM regulates its trafficking within different membranous system in the cell. PAM present in 
multi-vesicular bodies can either be subjected to degradation in lysosomes or secreted out of the cell in the form of 
exosomes
199
.
PAM sfCD mediated 
signaling
Maturation and 
secretion or plasma 
membrane localization of
PAM
Internalization of 
PAM in MVBs
Degradation in 
Lysosomes
Secretion of 
PAM via exosomes
Golgi vesicle
Cytoplasm
Nucleus
Lysosome
MVBs
Extracellular 
Matrix
Exosomes from MVBs
PAM  either on PM or 
secreted out as soluble 
form (with cleaved TM) 
PAM sfCD
AIM OF THE STUDY 
 
22 
  
1.6 Aim of the Study 
Glioblastoma is the most aggressive form of primary brain tumor with less than 15 months of median 
patient survival. The main reason behind this poor prognosis is its intra-tumoral genetic heterogeneity 
which leads to a highly resistant phenotype showing a high rate of neo-vasculature formation, diffused 
growth and modulation of the tumor microenvironment jeopardizing the current therapy regimen. This 
aggressive phenotype renders the tumor cells with high level of ER stress activating unfolded protein 
response (UPR) which supports them at almost every stage of tumor progression starting from the 
transformation and proliferation to their invasion to distant locations thus becoming one of the leading 
pathways promoting tumor growth. In order to better understand the role of the UPR in glioblastoma to 
target it effectively, the main theme of the PhD thesis is to determine hypoxia-led regulation of UPR in the 
tumor progression and identify potential therapeutic targets against its different hallmarks. To address 
these questions, we first characterized the activation of UPR in glioblastoma cells under artificial 
(Tunicamycin or thapsigargin) and a physiological (hypoxia) ER stress inducer, in regulating different UPR 
branches. UPR-mediated changes in the secretome of hypoxia treated glioblastoma cells was analyzed 
later using mass spectrometry based on specific UPR sensor protein. A potential hit thus identified was 
validated and characterized for its regulation with the specific UPR sensor and its role in regard to 
angiogenesis in glioblastoma. Pro-tumorigenic benefits of the target protein were studied in xenograft 
mouse model.  
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2. Materials & Methods 
2.1 Materials 
2.1.1 Antibodies 
Antibody Product Number 
Anti-PERK Cell Signaling (3192S) 
Anti-Goat, HRP couple Santa Cruz Biotech, Heidelberg, Germany 
Anti-Guinea pig, HRP coupled Santa Cruz Biotech, Heidelberg, Germany 
Anti-eIF2α Cell signaling (9722S) 
Anti-eIF2S1 Abcam (ab32157) 
Anti-mouse, HRP coupled Cell Signaling Technology, Danvers, USA 
Anti-ATF6α Novus Biologicals (NBP1-40256) 
Anti-IRE1α Santa Cruz (sc-20790) 
Anti-P-IRE1α Thermo Scientific (PA1-16927) 
Anti-EEF2 Santa Cruz (sc-166415) 
Anti-PAM Abcam (ab109175) 
Anti-ATF4 Cell Signaling (11815S) 
Anti-rabbit, HRP coupled Cell signaling Technology, Danvers, USA 
Anti-CHOP Cell Signaling (2895S) 
Rabbit anti-human IgG Control Jackson’s Immuno Research (309-005-008) 
Mouse IgG Control Santa Cruz, Heidelberg, Germany 
Anti-α-HIF1α Cell Signaling (3716S) 
Anti-FOSL1 Santa Cruz (sc-605) 
Anti-c-JUN Santa Cruz (sc-1694) 
Anti-P-c-Jun Santa Cruz (sc-16311R) 
Anti-Hevin Santa Cruz (sc-165539) 
Anti-CTGF Santa Cruz (sc-14939) 
Anti-CYR61 Santa Cruz (sc-13100) 
Anti-XBP1s Biolegend (619502) 
Anti-GRP78 (BIP) Santa Cruz (sc-1050) 
 
2.1.2 Buffers  
Buffers  Composition  
1x Phosphate buffered saline (PBS)  
137 mM NaCl, 2.7 mM KCl, 9.2 mM Na2HPO4, 1.8 mM 
KH2 PO4, pH 7.4 
1x Transfer buffer  25 mM Tris, 200 mM glycine, 20 % methanol, pH 8.8 
1x TRIS buffered saline (TBS)  150 mM NaCl, 10 mM Tris, pH 7.5 
1x TRIS-Borat-EDTA (TBE)  0.445 M Tris-Borat, 10 mM EDTA, pH 8  
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Blocking buffer  5 % milk powder or 5 % BSA in TBS-T 
Loading buffer (6x)  30 % Glycerine, 0.25 % Bromophenol blue  
 
2.1.3 Bacterial Culture Media 
Medium Composition 
LB (Luria-Bertani) 
0.5 % (w/v) NaCl, 1 % (w/v) Tryptone, 0.5 % (w/v) Yeast 
extract 
LB Agar 
0.5 % (w/v) NaCl, 1 % (w/v) Tryptone, 0.5 % (w/v) Yeast 
extract, 1.6 % (w/v) Agarose 
 
2.1.4 Biochemical Reagents 
Reagent Product Number 
Agarose  Sigma-Aldrich, Munich, Germany  
Ampicillin Roche Diagnostics, Mannheim, Germany 
Bicinchoninic acid (BCA) Sigma-Aldrich, Munich, Germany 
Bovine serum albumin New England Biolabs (NEB), Ipswich, USA 
Bromophenol blue  Waldeck GmbH, Münster, Germany 
Complete mini protease inhibitors Roche Diagnostics, Mannheim, Germany 
cOmplete
TM
, EDTA free protease inhibitor 
cocktail 
Roche Diagnostics, Mannheim, Germany 
Dithiotreitol (DTT) (0.1 M) Thermo Fischer Scientific, Langenselbold, Germany  
DNA loading dye (6x) Thermo Fischer Scientific, Langenselbold, Germany 
DNA marker (1kb)  Fermentas, St Leon-Rot, Germany  
dNTP mix (100 μM each)  Thermo Fischer Scientific, Langenselbold, Germany 
Ethanol Merck Millipore, Darmstadt, Germany 
Ethidium bromide  Sigma-Aldrich, Munich, Germany 
Ethyl acetate, 99.7 % Sigma-Aldrich, Buchs SG, Switzerland 
Ethylendiaminetetracetate (EDTA) (25 mM) Thermo Fischer Scientific, Langenselbold, Germany 
Glycerol Carl Roth, Karlsruhe, Germany 
Hardset antifade mounting medium with 
DAPI 
Vector Laboratories, Burlingame, USA 
Histoplast parafin Thermo Fischer Scientific, Langenselbold, Germany 
IP lysis buffer Thermo Fischer Scientific, Langenselbold, Germany 
Methanol  Sigma-Aldrich, Munich, Germany 
Nuclease-free water   Ambion, Austin, USA  
NuPAGE
®
 LDS sample buffer (4x) Life Technologies, Darmstadt, Germany 
NuPAGE
®
 SDS running buffer (20x) Life Technologies, Darmstadt, Germany 
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Oligo-d(T) nucleotides  Thermo Fischer Scientific, Langenselbold, Germany 
Paraformaldehyde (PFA)  Sigma-Aldrich, Munich, Germany  
PCR nucleotide mix  Roche Diagnostics, Mannheim, Germany 
Pierce ECL Western blotting substrate Thermo Fischer Scientific, Langenselbold, Germany 
Random primer mix New England Biolabs NEB), Ipswich, USA 
RIPA-lysis buffer Sigma-Aldrich, Munich, Germany 
Sodium dodecyl sulfate (SDS)  Sigma-Aldrich, Munich, Germany 
Sodium fluoride (NaF) Carl Roth, Karlsruhe, Germany 
Sodium orthovanadate (Na3VO4) Carl Roth, Karlsruhe, Germany 
Spectra multicolor broad range protein ladder Fermentas, St Leon-Rot, Germany 
Tris-(hydroxymethyl)-aminomethan (TRIS)  Carl Roth, Karlsruhe, Germany  
Triton X-100 Sigma-Aldrich, Munich, Germany 
Tween-20  Sigma-Aldrich, Munich, Germany 
Whole milk powder Carl Roth, Karlsruhe, Germany 
 
2.1.5 Cell Culture Reagents and Materials 
Article Company 
2-Mercaptoethanol, 98 % Sigma-Aldrich, Munich, Germany 
96-well plates (white, non-binding with clear 
bottom) 
Greiner/Sigma-Aldrich, Munich, Germany 
Accutase solution Sigma-Aldrich, Munich, Germany 
Cryo tubes Nunc, Wiesbaden, Germany 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich, Munich, Germany 
DMEM (Dulbecco’s modified eagle medium) Sigma-Aldrich, Munich, Germany 
Fetal calf serum (FCS) Merck Millipore, Darmstadt, Germany 
Horse serum Merck Millipore, Darmstadt, Germany 
L-Glutamine Thermo Fischer Scientific, Langenselbold, Germany 
Opti-MEM I reduced serum medium Thermo Fischer Scientific, Langenselbold, Germany 
PBS  Thermo Fischer Scientific, Langenselbold, Germany 
Penicillin/Streptomycin (10000 U/ml, 100 
µg/ml) 
Thermo Fischer Scientific, Langenselbold, Germany 
Puromycin VWR International, Darmstadt, Germany 
Reservoir (sterile) Corning inc., Corning, USA 
Syringe filters (0.45 µm) Merck Millipore, Darmstadt, Germany 
TransIT
®
-LT1 transfection reagent Mirus Bio, Madison, USA 
Trypsin EDTA solution (0.5 %) Sigma-Aldrich, Munich, Germany 
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2.1.6 In vivo Reagents and Materials 
Article Company 
Isoflurane Abbott, Wiesbaden, Germany 
Nanofil needle with syringe World Precision Instruments, Sarasota, USA 
Small animal stereotaxic instrument, model 
900 
David Kopf Instruments, Tujunga, USA 
VivoGlo
TM
 luciferin Promega, Madison, USA 
 
2.1.7 Mice 
Strain Source 
Nonobese diabetic/severe combined 
immunodeficiency (NOD-SCID)
®
 
In-house breeding facility of the DKFZ, Heidelberg, 
Germany 
 
2.1.8 Cell Lines 
Glioblastoma Stem-like Cell Lines 
GSC lines were obtained from Christel Herold-Mende at the Division of Experimental Neurosurgery in the 
University of Heidelberg. 
Cell Line Sex Age (Years) OS** (Months) 
NCH421k M 66 34 
NCH711d M 20.4 N/A* 
NCH644 F 67 30 
NCH705 N/A* 78 24 
 
N/A* not available 
2.1.9 Other Cell Lines 
Cell Line Origin Source 
LN308 Human glioblastoma (Bady et al., 2012) 
LN229 Human glioblastoma (Weiler et al., 2014) 
HEK293T Human Embryonic Kidney ATCC, Wesel, Germany 
Normal Human Astrocytes Human Brain 
Kindly provided by Andreas von Deimling, 
Department of Neuropathology, DKFZ, 
Heidelberg, Germany 
NCH82 Human glioblastoma (Karcher et al., 2006) 
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2.1.10 Bacteria 
Cells Supplier 
OneShot
®
 STABL3 chemically competent 
E.coli 
Thermo Fischer Scientific, Langenselbold, Germany 
 
2.1.11 Enzymes 
Enzyme  Company  
Age I (10 U/µl) Thermo Fischer Scientific, Langenselbold, Germany 
DNase I (1 U/μl)  Thermo Fischer Scientific, Langenselbold, Germany  
EcoRI (10 U/μl)  Thermo Fischer Scientific, Langenselbold, Germany 
PRECISOR High-Fidelity DNA Polymerase BioCat, Heidleberg, Germany  
RNase I (1 U/μl) Thermo Fischer Scientific, Langenselbold, Germany 
SuperScript II Reverse Transcriptase  Thermo Fischer Scientific, Langenselbold, Germany 
Xbal (10 U/μl) Thermo Fischer Scientific, Langenselbold, Germany 
 
2.1.12 Databases 
Databases  Address  
cBioPortal for Cancer Genomics www.cbioportal.org/ 
Ensembl www.ensembl.org 
Gene Cards (Human Genes Database) www.genecards.org/ 
OligoCalc www.basic.northwestern.edu/biotools/oligocalc.html 
--PubMed www.ncbi.nim.nih.gov/PubMed/ 
Universal Protein Resource www.uniprot.org 
R2: Genomics Analysis and Visualization 
Platform 
https://hgserver1.amc.nl/cgi-bin/r2/main.cgi 
 
2.1.13 Equipment 
Equipment  Company  
Axioplan 2 microscope Carl Zeiss Microscopy, Jena, Germany  
Biofuge Fresco table top centrifuge Haraeus Instruments, Hanau, Germany 
Cytospin3-centrifuge  Thermo Fischer Scientific, Langenselbold, Germany 
Dynamag
TM
 magnet Thermo Fischer Scientific, Langenselbold, Germany 
Heating block QBT  Grant Instruments, Cambridge, UK 
HistoCore Arcadia embedding system Leica Biosystems, Wetzlar, Germany 
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Incubator HERA cell 150 Thermo Fischer Scientific, Langenselbold, Germany 
L8-M ultracentrifuge  Beckmann Coulter, Krefeld, Germany 
Leica TCS SP5 confocal microscope Leica Biosystems, Wetzlar, Germany 
Mini Trans-Blot
®
 cell Bio-Rad, Munich, Germany 
Mithras LB 940 plate reader Berthold Technologies, Bad Wilbad, Germany 
NanoDrop
®
ND-1000 spectrometer NanoDrop, Wilmington, USA 
QuickPoint electrophoresis cell Novex, Sandiego, USA 
Vortex Genie 2 Scientific Industries Inc., New York, USA 
Water bath B-480 Büchi, Flawil, Switzerland 
XCell SureLock™ Mini-Cell electrophoresis 
system 
Thermo Fischer Scientific, Langenselbold, Germany 
 
2.1.14 Kits 
Kit Company 
ABsolute SYBR
®
 Green ROX mix  Thermo Fischer Scientific, Langenselbold, Germany 
CellTiter-Glo
®
 luminescent cell viability assay Promega, Madison, USA 
Maxi preparation DNA kit  Qiagen, Hilden, Germany 
Mini preparation DNA kit Qiagen, Hilden, Germany 
Rapid DNA dephos and ligation kit Roche Diagnostics, Mannheim, Germany 
RNeasy
®
 Mini kit  Qiagen, Hilden, Germany 
 
2.1.15 Other Material 
Article Supplier 
96-well low profile PVS plate (skirted) Thermo Fischer Scientific, Langenselbold, Germany 
ABgene
TM
 adhesive PCR plate seals ABgene, Epsom, UK 
Cover slips (10 mm round) 
Thermo Fischer Scientific Gerhard Menzel, 
Braunschweig, Germany 
Cover slips (26 x 76 mm) 
Thermo Fischer Scientific Gerhard Menzel, 
Braunschweig, Germany 
Dynabeads
®
 Protein G Thermo Fischer Scientific, Langenselbold, Germany 
Glass slides Sigma Aldrich, Munich, Germany 
Glass vials Mikrolab Aarhus A/S, Viby, Denmark 
NuPAGE
® 
antioxidant Life Technologies, Darmstadt, Germany 
NuPAGE
®
 Bis-Tris precast gels (15 or 10 
well; 1.5 or 1 mm) 
Life Technologies, Darmstadt, Germany 
PCR tubes (0.2 ml) Molecular BioProducts, San Diego, USA  
Pipette tips (10 µl, 20 µl, 100 µl, 200 µl, 1000 
µl) 
Starlab, Ahrensburg, Germany 
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Polyvinylidene fluoride (PVDF) membrane Sigma Aldrich, Munich, Germany 
Reaction tubes (1.5 ml and 2 ml) Eppendorf, Hamburg, Germany 
X-ray films, Super RX  FUJIFilm, Tokyo, Japan 
 
2.1.16 Plasmids 
Commercially Available Plasmids (Plasmid maps are provided in the Appendix section) 
Plasmid Company 
pLKO.1 puro Addgene, Cambridge, USA 
pLVX-Puro Clontech, Mountain View, USA 
pMD2.G Addgene, Cambridge, USA 
psPAX2 Addgene, Cambridge, USA 
 
2.1.17 Generated Plasmids 
pLVX-tGFP 
pLVX-PAM 
pLKO-puro-shNT 
pLKO-puro-shPERK 
pLKO-puro-shPERK-2 
pLKO-puro-shPAM 
pLKO-puro-shGCN2 
pLKO-puro-shPKR 
pLKO-puro-shHRI 
pLKO.1-shNT-GFP-fLUC 
 
2.1.18 List of primers and shRNA target sequences 
List of primers used for quantitative PCR 
Name Forward Primer Reverse Primer 
XBP1s TGAGTCCGCAGCAGGTGCA CTGGGTCCTTCTGGGTAGACCTC 
NDRG1 GTTTCCTGGCGTCGTCTC ATGTCCCTGCTGTCACCTG 
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XBP1-EP CCTGGTTGCTGAAGAGGAGG CCATGGGGAGATGTTCTGGAG 
PAM TTACACCTCACACGTCTGCC ATCAACTGGATGCCCCACAG 
VEGF-A GGCCTCCGAAACCATGAACT TGGGACTTCTGCTCTCCTTCT 
HIF1α TCCATGTGACCATGAGGAAA CCAAGCAGGTCATAGGTGGT 
PERK GCCAATGACAGTAGCTGGAATG GTGTTCAAGCTTGGCTAAGGCTT 
EEF2 CTGGAGATCTGCCTGAAGGA GAGACGACCGGGTCAGATT 
RPS13 CCCAGTCGGCTTTACCCTAT GCCCTTCTTGGCCAGTTTGT 
List of shRNA target sequences  
Target Gene Target sequence 
PERK-1 GGCAACCATTGTGCTAATAAA 
PERK-2 GCCACTTTGAACTTCGGTATA 
HIF1α CCGCTGGAGACACAATCATAT 
PAM GCCTTTAATTGCTGGCATGTA 
Non-Target (NT) CAACAAGATGAAGAGCACCAA 
 
2.1.19 Software 
Software  Company  
Basic Local Alignment Search Tool (BLAST)  blast.ncbi.nlm.nih.gov 
GraphPad Prism 7 GraphPad, San Diego, USA 
ImageJ  rsbweb.nih.gov/ij 
Microsoft Excel 2010 Microsoft, Redmond, USA 
PlasMapper Version 2.0 wishart.biology.ualberta.ca 
 
 
2.2 Methods 
2.2.1 Cell culture 
LN308, LN229, NCH82 glioblastoma cells were cultured in DMEM (Sigma-Aldrich, Munich, Germany) with 
10% FCS (Merck Millipore, Darmstadt, Germany) and Penicillin/Streptomycin (10000 U/ml, 100 µg/ml; 
Thermo Fischer Scientific, Langenselbold, Germany). HUVECs cells were cultured in dishes pre-coated 
with 0.2% gelatin in dH2O. Endopan 3 medium (PAN biotech-P04-0010k) along with provided 
supplements was used to culture HUVECs and accutase (Sigma-Aldrich, Munich, Germany) was used to 
split these cells. Cells were regularly checked for mycoplasma contamination as per the 
recommendations of the German Collection of Microorganisms and Cells (Germany). Glioblastoma cell 
lines were authenticated using single nucleotide polymorphism profiling. GSCs were isolated from primary 
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GBM tumors resected from patients as per legal guidelines approved by Institutional Review board at the 
Medical Faculty of Heidelberg. Tumor samples were dissociated enzymatically to isolate cells which were 
cultured as neurospheres. The cells were grown in standard culture conditions (37°C, 95 % humidity and 
5 % CO2) in serum-free stem cell medium (DMEM/F-12 medium, 20 % (v/v) BIT-admixture and 20 ng/ml 
each of basal fibroblast growth factor (bFGF) and epidermal growth factor (EGF)).  
 
2.2.2 Lentivirus production 
Lentivirus was produced in HEK-293T cells using TransIT
®
-LT1 by transfecting a lentiviral construct of 
interest along with pMD2.G (Addgene, USA), psPAX2 (Addgene, USA). Conditioned media with the virus 
particles was pre-cleared via centrifugation for 5 min at 2000 rpm and filtered through 0.45 µm cellulose 
acetate filters (Merck-Millipore, Germany). Lenti-viral particles were harvested by centrifuging the cleared 
conditioned media for 90 min at 25000 rpm at 4°C using SW41 swing-out rotor in a L8-M ultracentrifuge. 
The virus particles were resuspended in PBS and stored at -80 °C. The virus titer was determined by 
infecting target cells using dilutions which resulted in linear relationship between the dilution and 
percentage of GFP-positive cells.  
 
2.2.3 pLKO.1 shRNA Cloning 
shRNA oligos (section 2.2.18) were primed at 95°C for 4 min using hybridization buffer (Tris HCl (pH 7.8), 
100 mM, NaCl 1M, and EDTA 10 mM). The primed oligos were then ligated into pLKO.1 vector digested 
with EcoRI and AgeI restriction enzymes using T4 DNA ligase (EL0011) overnight. The ligation mix was 
transformed in E. Coli DH5ɑ competent cells and colonies were confirmed for the presence of shRNA 
oligos first using colony screening PCR and later sequencing. 
 
2.2.4 Immuno-blotting 
Cells were lysed in 100 µl RIPA-lysis buffer (R0278-50ML) supplemented with 10 mM NaF, 10 mM 
Na3VO4 and complete mini protease inhibitor cocktail (Roche #11836170001). The lysed cells were 
centrifuged for 20 minutes at 13000 rpm. Protein extracts were stored at -80°C. Bicinchoninic assay was 
used to measure protein concentration. Protein samples were prepared using LDS sample buffer (Novex 
#NP0007) and equal amount of protein was loaded onto 4-12 % Bis-Tris Gels (40 µg from cell pellet and 
3 µg from conditioned media). Electrophoresis was performed at 250 V and 170 mA for 45 minutes in 
MOPS running buffer. Protein was later transferred on a PVDF membrane using a protocol having 
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subsequent increase in current every 10 minutes for 50 minutes (100, 200, 300, 400, 500 mA). The 
membrane was blocked, incubated with primary and subsequently with respective secondary antibody. 
The protein detection was done on X-ray films. 
 
2.2.5 Real-time PCR 
RNA isolation was performed using Qiagen RNA isolation kit (#74106) as per the product manual. 1 ug of 
RNA was used to synthesize cDNA using ProtoScript® II Reverse Transcriptase, NEB (#M0368L). Real 
time PCR was performed by mixing 10 ng of cDNA, 0.5 µM of forward & reverse primer each (final 
concentration; Appendix Table S2) and Qiagen SyBr green dye (#204057). LightCycler 480 instrument 
was used to perform the RT-PCR. 
 
2.2.6 Mass spectrometry experiment design 
1x10
6 
LN308 glioma cells were seeded and were allowed to grow until 70-80 percent confluency (2 days). 
The cells were washed and incubated in serum-free-DMEM. Overnight incubation of GSK2606414 (1 µM) 
was given as a PERK negative control. The next day, cells were incubated under hypoxic condition of 1% 
O2. After 72 hours incubation, the conditioned media was collected in 50 ml falcon and spin down at 2000 
rpm for 3 min. The conditioned media (free of debris) was collected in a new 50 ml falcon tube after 
filtering the content through a 0.45 µm filter. The filtered conditioned media was emptied in an Amicon 
Ultra-15 (PLGC Ultracel-PL Membrane, 10 kDa, UFC901008, EMD Millipore). The conditioned media was 
concentrated by centrifuging the filter at 4000 rpm for 15 min at 4 °C. The concentrated media content 
was collected in a 2 ml tube and snap frozen.  
 
2.2.7 Proteomics sample preparation 
Each sample type was prepared in three biological replicates. For the protein precipitation, 2.25 ml of ice 
cold ethanol was added to 250 µl of cell secretome samples. After ~16 hour of precipitation at -80°C, the 
protein pellets were collected by centrifugation at 18.000 g, 4 °C for 30 min. 20 µl of 6M Guanidine-
Hydrochloride (Gu-HCl, Sigma-Aldrich, USA) was used to dissolve the protein pellets. 50 mM of 
NH4HCO3 (pH 7.8, Sigma-Aldrich, USA) was added to dilute the concentration of Gu-HCl to 0.6 M for the 
protein amount determination using bicinchoninic acid assay (Pierce™ BCA Protein Assay Kit, 
ThermoFisher Scientific™ Hamburg Germany).The samples were then reduced with 10 mM final 
concentration of Tris (2-carboxyethyl) phosphine hydrochloride (TCEP, Sigma-Aldrich, USA) at 56 °C for 
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30 min, alkylated with 30 mM Iodoacetamide (IAA, Sigma-Aldrich, USA) at 25 °C in dark chamber for 30 
min and diluted to 0.2 M Gu-HCl with 50 mM of NH4HCO3 (pH 7.8) for Trypsin digestion. Trypsin (Trypsin 
Gold, Promega, USA) was added at a ratio of 1:50 (w/w, protease to substrate) for the enzymatic 
digestion. The digestion was performed for maximum 15 hours at 37 °C. The digestion was stopped by 
acidifying with 10% trifluoroacetic acid (TFA) until pH <2. The peptide samples were desalted using solid 
phase extraction method utilizing SepPak C18 cartridges (100 mg sorbent per cartridge, Waters, USA). 
The cartridges were preconditioned twice with 1 ml methanol each time and then equilibrated three times 
with 0.1% TFA. The peptide samples were loaded onto the cartridges. After washing three times with 1 ml 
0.1% TFA, they were eluted with 80% acetonitrile (ACN), 0.1% formic acid (FA) and dried under vacuum. 
The dried peptides were dissolved in 0.1% TFA and stored at -80°C for further analysis. The digestion 
quality was checked by monolithic reverse phase separation as described in Burkhart et al. 2012. 
 
2.2.8 LC-MS/MS analysis 
1µg of peptide was used per injection on an Ultimate 3000 Rapid Separation Liquid Chromatography 
(RSLC) nano system coupled to a Q-ExactivePlus mass spectrometer (both ThermoFisher Scientific, 
Germany). Peptides were trapped on a pre-column (Acclaim C18 PepMap100, 100 µm 2 cm, 
ThermoFisher Scientific, Germany) using 0.1% TFA at a flowrate of 20 µl/min and subsequently 
separated on a reverse phase main-column (Acclaim C18 PepMap100, 75 µm-50 cm, Thermo Scientific, 
Germany) using a binary gradient consisted of A: 0.1% formic acid (FA) and B: 84% acetonitrile, 0.1% FA 
at a flow rate of 250 nl/min. The linear gradient was run from 3 to 42% for 180min at a flow rate of 250 
nl/min. For the mass spectrometry (MS) analysis, full MS scans were acquired at a resolution of 70.000 
full width at half maximum (FWHM), target value of 3e6, maximum injection time of 120 ms. Data 
dependent MS scans were acquired using high-energy collisional dissociation (HCD) on 15 most 
abundant ions (top15) at normalized collision energy of 27%, resolution of 17.500 FWHM, isolation 
window of 1.2 m/z, target value of 5e4 and maximum injection time of 250 ms. Only precursor ions with 
charge states between 2 and 4 will be fragmented.  
 
2.2.9 Label free data analysis 
For the data analysis, Progenesis QI for Proteomics software (version 3.0 Non-Linear Dynamics) was 
used. The peptide identification was done using two search algorithms: X!Tandem 
224
 via SearchGUI 
interface version 2.5.0 
225
 and Mascot 2.4 (Matrix Science). The Uniprot human database (downloaded on 
22sd of July 2015) was used with the following search parameters: Trypsin as protease (maximum 2 miss 
cleavages), fixed modification: carbamidomethylation at cysteine, variable modification: oxidation at 
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methionine, 10 ppm as MS1 tolerance and 0.02 Da as MS2 tolerance. To combine search results from 
X!Tandem and Mascot, PeptideShaker version 1.9.0 
226
 was used at a false discovery rate of 1 %. Only 
proteins identified with at least 2 unique peptides were considered for the final analysis. The statistical 
data analysis was performed using R version 3.3.1 (codename "Bug in Your Hair"). For the calculation 
and data formatting, packages reshape2 were used and for the graphical illustrations ggplot2andgridExtra 
packages were used. The significance P-value was calculated using function t-test (Student’s t-test, two-
sided, true variance equality, confidence level at 0.95). Proteins were considered to be differentially 
regulated, if their P-value was below 0.05 and the fold change was greater than 2 (up-regulated) or less 
than 0.5 (down-regulated). The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE 
227
 partner repository with the dataset identifier PXD012523 
and 10.6019/PXD012523. 
 
2.2.10 Data availability 
Mass spectrometry dataset generated and analyzed in this study is available on ProteomeXchange: 
PRIDE PXD012523 
(https://www.ebi.ac.uk/pride/archive/projects/PXD012523)  
 
2.2.11 PHM activity 
Cells were lysed in 10 volumes of buffer containing NaTES–mannitol–Triton X-100 (TMT) (pH 7.4) and 
protease inhibitors, as previously described
228
. Protein concentrations were determined using BCA 
reagent (Pierce). Samples were diluted 10-fold in PHM diluent (TMT containing 1 mg/ml bovine serum 
albumin) and incubated at 37°C for 1 h in the presence of 125I-Acetyl-Tyr-Val-Gly, CuSO4 and ascorbate 
(for PHM assays) or 125I-Acetyl-Tyr-Val-(OH)-Gly (for PAL assays)
228
. Uncharged amidated product was 
extracted with ethyl acetate and counted. Data were converted to picomoles of the product per microgram 
of protein per hour (pmol/μg protein/h) and analyzed with unpaired t tests. Each sample was assayed in 
triplicate. 
                                                                                                                                                       
2.2.12 Immunofluorescence 
The coverslips were washed with PBS twice and the cells were fixed using 4% formaldehyde overnight, 
washed thrice in PBS and blocked in blocking buffer (1X PBS/5% normal serum/0.3% Triton™ X-100) for 
60 min. The coverslips were incubated with antibody dilution (diluted in 1X PBS/1% BSA/0.3% Triton™ X-
100) for overnight at 4°C (PERK ab (AF3999-SP)), rinsed thrice with PBS and incubated with 
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Fluorochrome-conjugated secondary antibody for 1–2 hr at room temperature in the dark and humid 
environment. ab150089 and ab150132 secondary antibodies were used having Alexa488 and Alexa594 
labels respectively. After secondary antibody incubation the coverslips were mounted with Vectorsheild 
DAPI-mount (#H-1200) onto a glass slide. The images were taken using Leica SP5 confocal microscope. 
 
2.2.13 Dynabeads immunoprecipitation 
Cells were lysed using Pierce IP-lysis buffer (#87787). The supernatant was collected in new tubes and 
pre-cleared using 25 µl of Dynabeads Protein G (Invitrogen #10003D) for an hour at 4°C. In parallel, 25 µl 
of Dynabeads were washed with PBS-Tween20 (0.1%) and incubated with 1 µg of antibody for 20 min at 
room temperature on a rocker in 200 µl PBS-Tween20 (0.1%). Later, 500 µg of protein from the pre-
cleared lysate was incubated with the Dynabeads-Antibody complex making a final volume of 500 µl in 
IP-lysis buffer for overnight at 4°C. The Dynabeads were washed with 500 µl PBS-Tween20 (0.1%) thrice 
and boiled at 95°C for 4 min after resuspending in 5x Laemmli buffer and loaded onto SDS-PAGE gel. 
 
2.2.14 Extracellular vesicle isolation 
The conditioned media was collected and taken through sequential centrifugation steps in order to obtain 
clean extracellular vesicle fraction. The conditioned media was first centrifuged at 1500 rpm for 10 min to 
remove cell debris. Supernatant was collected and centrifuged at 2500 rpm for 10 min and 4000 rpm for 
30 min. The supernatant was used in each step for further processing. The final step involved the 
centrifugation of collected supernatant at 25000 rpm for 3 hours to obtain extracellular vesicles. The 
supernatant was discarded and pellet obtained was either resuspended in RIPA for western blotting or 
reconstituted in PBS overnight at 4°C for electron microscopy imaging. 
 
2.2.15 Electron Microscopy  
For electron microscopy (EM) extracellular vesicles from purified preparations were adsorbed onto glow 
discharged carbon coated formvar grids, washed in buffer and negatively stained with 2% aqueous uranyl 
acetate. For immuno-EM, the immuno reaction was performed after buffer wash including incubation with 
blocking agent (Aurion, Wageningen, The Netherlands), dilution series of primary antibody and Protein A-
Au reporter (CMC, UMC Utrecht, The Netherlands). Micrographs were taken with a Zeiss EM 910 at 
100kV (Carl Zeiss, Oberkochen, Germany) using a slow scan CCD camera (TRS, Moorenweis, 
Germany). 
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2.2.16 TCA protein precipitation  
Conditioned media was collected and spun down to remove cell debris. The supernatant was then mixed 
with trichloroacetic acid (TCA) making a final concentration of 10%, and kept at 4°C overnight on ice. The 
tubes were centrifuged at 13000 rpm for 30 min to pellet down the precipitated protein. Supernatant was 
discarded and the pellets were washed twice with acetone (kept at -20°C) by centrifuging at 13000 rpm 
for 30 min. Later, the pellet was dried for two minutes to remove excess of acetone and re-suspended in 
RIPA buffer. Equal amount of protein was loaded for SDS-PAGE. 
 
2.2.17 Total binding affinity analysis for PAM promoters 
Genome-wide total binding affinities (TBA) for transcription factors of all promoters of protein-coding 
genes was performed as follows: Curated gene transcript annotation was downloaded (December 20, 
2018) from the RefSeq track of the UCSC Genome Browser (human reference genome GRCh38/hg38) 
229
 and filtered for transcripts which contain coding sequences. A promoter was defined as the region 
spanning from 1500 bases upstream to 500 bases downstream (with respect to the transcription strand) 
of the transcription start site (TSS). For genes with multiple TSS, all promoters were considered 
individually, resulting in a total of 25,387 promoters of 19,301 protein-coding genes. Position frequency 
matrices (PFM) were obtained from JASPAR (release 7, 2018) 
230
for core matrices of a total of 579 
vertebrate TF, using the R package JASPAR2018 (version 1.1.1) 
(https://bioconductor.org/packages/release/data/annotation/html/JASPAR20). For each promoter and 
each TF, we computed the binding affinity using the R package MatrixRider (version 1.12.0) 
(https://bioconductor.org/packages/release/bioc/html/MatrixRider.html) with a cutoff of zero for 
getSeqOccupancy(), corresponding to the TBA, i.e., the binding affinity summed over the entire promoter 
rather than over individual TF binding sites 
231
. The resulting set of 25,387 TBA obtained for each TF was 
transformed first by taking the logarithm (base 2) and then by computing the corresponding z-score (i.e., 
the number of standard deviations it is above or below the mean log2-transformed TBA for that TF). This 
transformation allows for better comparability between TBA of different TF because the raw TBA scores 
highly depend on both the length and the information content of the different binding motifs. 
 
2.2.18 Tube formation assay 
As described previously, the tube formation assay was performed by coating wells of a 48-well plate with 
150 µl of growth factor reduced matrigel (Product #356230; Corning) and allowed to polymerize for 10 
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min at 37°C 
232
. HUVECs were detached using accutase and resuspended in a concentration of 80,000 
cells per 800 µl. 250 µl of cell suspension was added to each well coated with matrigel and the plate was 
incubated at Incubate plate at 37°C and 5%CO2. The tubes formed by HUVECs were imaged using Axio 
Vert.A1microscope. The quantification was done manually. A junction is identified as a point where more 
than 2 segments meet whereas a mesh is identified as a closed network formed by the segments. A 
segment is a tube formed between two different junctions. The measurement was done manually. 
 
2.2.19 Animal experiments 
Anesthetized male NSG mice (NOD SCIDγ Jackson, USA), 10-12 weeks of age, were given an analgesic 
and xenografted with 8 × 10
4 
LN308 glioma cells expressing GFP and luciferase (stably integrated in the 
cells using a pLKO lentiviral backbone), at a position 1 mm lateral and 2 mm posterior from the bregma. 
Mice with neurological symptoms or a weight loss of >20% were euthanized. All animal procedures were 
conducted in accordance with the institutional animal research guidelines after obtaining approval from 
the regional commission of Karlsruhe, Baden-Wuerttemberg, Germany (file number G127-16). Survival 
was compared using the log-rank test. 
 
2.2.20 Bioluminescence imaging 
All mice were imaged at day 7 and 14 post tumor cell injection. D-luciferin was injected at a concentration 
of 150 mg/kg body weight (Biomol, Germany). Mice were anaesthetized using 1.5 % of isoflurane (Abbott, 
Germany). After 10 min incubation, images were acquired using an IVIS Lumina II system (Caliper Life 
Science, USA) with exposure times of 1, 3 and 5 min. Total bioluminescence flux signals (photons/sec) 
were quantified with LivingImage 4.4 (PerkinElmer, USA) as a measure of tumor burden. 
 
2.2.21 Statistics 
Excel 2010 and GraphPad Prism 7 were used to carry out statistical testing. Experiments were performed 
in biological triplicate (unless otherwise mentioned) and data provided in the manuscript represents the 
mean ± standard error. Unpaired two sided student’s t-test was used to determine level of significance. 
Log rank (Cox-Mantel) test was used to calculate the difference in the distribution of survival data in 
Kaplan Meier analysis. 
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3. Results 
Identification of extracellular matrix proteins regulated by UPR under in 
glioblastoma 
The text and the figures in this section have been adapted from Soni et al., submitted, and correspond to 
my PhD research project. 
3.1 Methodology to decipher the role of hypoxia-induced UPR in expression of 
extracellular proteins 
To understand the role of UPR in modulating the secretome of glioblastoma, we first characterized UPR 
in LN308 glioblastoma cell model using artificial ER stress inducers. We then identified the activation 
status of different sensors of the UPR under hypoxic condition (Figure 9) and determined extracellular 
matrix proteins which the hypoxia-activated UPR branch, already known to regulate angiogenesis, might 
induce, using proteomics approach. Later, we validated and characterized the potential target. We also 
studied the phenotypic role of the target in glioblastoma context and subsequently validated the 
phenotype in vivo. 
 
Figure 9. Experimental strategy to determine the UPR-regulated angiogenic targets under hypoxia in 
glioblastoma cell model. 
Hypoxia
Mass 
spectrometry
for target 
selection
Validation in 
mouse model
Pathway 
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Dynamic modulation 
of UPR under hypoxia
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3.2 Characterization of UPR induction in glioblastoma using artificial ER stress 
inducers 
3.2.1 Activation of UPR pathway proteins: IRE1 and PERK 
To understand the dynamics of signaling of different UPR sensors in glioblastoma, we first characterized 
IRE1α branch of the UPR in glioblastoma cells using artificial ER stress inducers. We examined the 
phospho-state of IRE1α at Serine 724 residue under tunicamycin treatment. For this, we treated LN308 
cells with tunicamycin for 4 hours and harvested the cells, and later immuno-precipitated P-IRE1α 
population. Figure 10A shows a prominent increase in the P-IRE1α levels under tunicamycin treatment as 
compared to the vehicle control suggesting an activation of IRE1α by autophosphorylation at Serine 724 
residue. Next, we treated the glioblastoma cell lines (LN229 and LN308) and HEK293 cells (a non 
glioblastoma model) with 2.5 µg/ml of tunicamycin for different time points and analyzed the splicing 
activity of its RNase domain towards XBP1 mRNA. Tunicamycin is a nucleoside antibiotic that inhibits N-
linked glycosylation of newly synthesized polypeptide chains, specifically inhibiting protein folding and 
secretion via Golgi vesicles. The accumulation of misfolded proteins in the ER leads to UPR activation. All 
three cell lines showed activation of XBP1 splicing within 4 hours of tunicamycin treatment (Figure 10B-
D). While both HEK293 and LN308 cells showed an oscillatory pattern of XBP1s mRNA generation with 
time under ER stress, we observed a comparatively reduced IRE1α RNase activity in LN308 cells during 
the second cycle after 16 hours of tunicamycin treatment in comparison to HEK293 cells suggesting a 
better adaptation of LN308 cells to ER stress. We also compared the effect of tunicamycin with another 
artificial inducer of UPR, thapsigargin. Thapsigargin is a non-competitive inhibitor of calcium transport via 
sarco/endoplasmic calcium ATPases (SERCAs) which causes an increase of cytosolic calcium levels. 
This reduces the availability of calcium for ER chaperones and leads to accumulation of miss-folded 
proteins within the ER. Both tunicamycin and thapsigargin showed similar induction of Hspa5, a well 
known ER chaperone expressed under UPR activation, and XBP1s mRNA (Figure 10E). This suggests a 
simultaneous phosphorylation of IRE1α and generation of XBP1s in LN308 cells under artificially induced 
ER stress condition. The data also postulates a dynamic nature of IRE1α during UPR where its activation 
reduces gradually with time to possibly maintain a pro-survival effect, but is increased again potentially 
due to inability of the UPR to cope with accumulating ER stress.  
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Figure 10. ER stress induced IRE1α activation in glioblastoma cells. 
A) Level of immuno-precipitated P-Ser724 IRE1α in LN308 cells treated with tunicamycin (2.5 µg/ml) for 4 hours. 
Agarose gel showing IRE1α-mediated generation of XBP1s in LN229 (B), LN308 (C) and HEK293 (D) cells treated 
with tunicamycin (Tm) for indicated time-points. β-actin was used as a housekeeper. E) LN229 glioblastoma cells 
were treated with 2.5 µg/ml of tunicamycin and 200 nM of thapsigargin (Tg) for respective time points to determine 
and quantify the expression pattern of Hspa5, XBP1s and XBP1u mRNA levels. The relative expression of 3 
independent biological replicate were averaged and plotted with standard error. ARF1 was used as a housekeeper. 
Note: Lane 7 does not show any band for β-actin amplification possibly due to technical error. 
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Next we characterized the activation of PERK branch of UPR in LN308 cells under artificial stress 
condition. We then treated the cells for 6 and 16 hours with tunicamycin and analyzed the activation of 
PERK, expression of ATF4 and phosphorylation of eIF2α (Figure 11). The result shows a prominent 
increase in the expression of ATF4, an upshift in the total PERK protein (indicator of PERK activation) 
and a slight increase in the P-eIF2α populations after induction of UPR for 6 hours. Interestingly we 
observed a reduction of PERK downstream effects after 16 hours of tunicamycin treatment in LN308 cells 
which can be a result of negative feedback loop to reduce the intensity of UPR activation in glioblastoma 
cells, in the same manner as observed in case of IRE1α and indicate towards adaptation of these cells to 
the ER stress condition. 
 
 
Figure 11. ER stress induced PERK activation in LN308 glioblastoma cells. 
Levels of ATF4, P-eIF2α and PERK proteins in LN308 cells treated with tunicamycin treated for indicated time-points.  
 
3.2.2 Small molecular inhibitors of UPR sensor proteins 
Understanding branch specific role of UPR in glioblastoma is essential to target it effectively. For this 
purpose we tested specific inhibitors of IRE1α (STF083010), PERK (GSK2606414) and ATF6α (Ceapin 
A7) under tunicamycin-induced ER stress condition and determined the optimum concentration of these 
inhibitors to be further used for proteome analysis using LN308 glioblastoma cell line model. STF083010, 
a IRE1α RNase specific inhibitor showed maximum efficiency to inhibit XBP1 splicing at 50 µM (Figure 
12A) while GSK2606414 showed maximum inhibition of PERK at 1 µM of concentration (Figure 12B) as 
seen by the mobility shift in the total PERK protein. For the inhibition of ATF6α branch, we used already 
known concentration of Ceapin A7 (1µM) which was shown to decrease tunicamycin-induced expression 
of Bip at both mRNA and protein levels (Figure 12C and D).  
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Figure 12. Small molecule inhibitors of UPR pathway. 
A) Agarose gel showing reduced splicing of XBP1 mRNA in LN308 cells under the influence of IRE1α RNase 
inhibitor, STF083010. B) β-actin was used as a housekeeper. GSK2606414-mediated reduction in mobility shift of 
total-PERK under ER stress condition in LN308 cells. C) Reduced levels of Bip and EDEM mRNA when ceapin A7 
was used to inhibit ATF6α during tunicamycin-induced ER stress in LN308 cells. RPS13 was used as a housekeeper. 
D) Effect of Ceapion A7 on Bip protein under tunicamycin-induced UPR. EEF2 was used as a loading control. 
 
3.2.3 IRE1-mediated regulation of invasive markers in glioblastoma 
IRE1α is known to negatively regulate the expression of various invasive proteins by targeting and 
degrading their mRNA, an activity known as Regulated IRE1α Dependent Decay (RIDD). To understand 
and validate few of the known invasive proteins being regulated by IRE1α we used a specific activator 
and inactivator of its RNase domain, APY29 and STF083010, respectively (Figure 13). We used 
nocodazole, an actin cytoskeleton regulator known to regulate SPARC via IRE1α, as a positive control for 
the experiment known to inhibit IRE1α activity. CYR61, CTGF and Hevin proteins expression increased 
under nocodazole treatment, a phenomenon which was subsequently inhibited when IRE1α was 
activated by APY29. STF083010 slightly increased the expression of CTGF among other IRE1 target 
proteins showcasing basel level activation of IRE1α in LN308 glioblastoma cells. In this respect, we justify 
that it is of high importance to proceed with the high throughput mass spectrometry screen and identify 
branch specific role of UPR in glioblastoma secretome. 
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Figure 13. IRE1α-mediated regulation of extracellular proteins in LN308 glioblastoma cells. 
Expression of Hevin, CTGF and CYR61 under the influence of IRE1α specific modulators, STF083010 and APY29 in 
LN308 glioblastoma cells for 24 hours. Nocodazole was used as a known inducer of SPARC.  
 
3.3 Selective activation of UPR sensors under hypoxia in glioblastoma 
During tumor progression, the glioblastoma cells confront different stress conditions including mechanical 
stress, loss of nutrients and hypoxia which activates UPR. As hypoxia is highly potent in selecting cells 
engaged in inducing angiogenesis, invasion and secretion of factors responsible for modulating tumor 
microenvironment, we chose to continue our study with this physiological ER stress inducer and 
determine hypoxia-induced UPR branch-specific regulation of extracellular matrix proteins. In order to 
understand this, we first analyzed which UPR branch is affected by hypoxic condition in glioblastoma 
cells. We treated glioblastoma cells with 1% O2 and checked for the activation of PERK, ATF6α and 
IRE1α activation status. Activation of PERK (as indicated by mobility shift in total PERK and 
phosphorylation of eIF2α) was evident in glioblastoma cells under hypoxia, although it was less robust as 
compared to hypoxia-induced PERK in HEK293 (Figure 14A and B). Hypoxia also resulted in the 
formation of active cleaved ATF6α (50 kDa) in LN308 glioblastoma cells initially, but this decreased after 
48 and 72 hours of hypoxia treatment indicating a potential adaptation to the stress conditions (Figure 
14C). 
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Figure 14. Activation of PERK and ATF6α branch of UPR in glioblastoma cells under hypoxia. 
Total PERK, eIF2α and P-eIF2α expression in HEK293, LN308 (A) and LN229 (B) cell lines under normoxia or 
hypoxia. EEF2 was used as a loading control. B) Active form of ATF6α (50 kDa band) in LN308, under hypoxia for 
24, 48 and 72 hours. Adapted from Soni et al., submitted. 
 
Unlike in HEK293 cells, IRE1α was not active in glioblastoma under hypoxia as demonstrated by the 
absence of XBP1s mRNA, a downstream product of the active-IRE1α RNase domain and by the 
decrease in phosphorylated IRE1α (necessary for the activation of its kinase activity; Figure 15A-F). The 
data suggests that glioblastoma cells are better equipped to tolerate hypoxia than HEK293 cells, and 
highlights a possible selective activation of UPR branches under hypoxia in glioblastoma in vitro. 
 
Figure 15. Reduced activation of IRE1 under hypoxia in glioblastoma. 
Total amount of XBP1s mRNA transcripts in HEK293 (A) and LN308 (B) cells treated with hypoxia for 24, 48, 72 
hours. C) XBP1s mRNA level as determined by qRT-PCR in LN308 and LN229 cell lines under hypoxia. NDRG1 was 
taken as a positive control for hypoxia induction. RPS13 was used as housekeeping gene. Data are normalized to the 
respective normoxic conditions and are represented as the mean of three independent experiments ± SEM (T-test: 
*p-value < 0.05, ** p-value < 0.01). D) Total P-IRE1α species immunoprecipitated using P-IRE1α antibody from 
LN308 cells treated with hypoxia for 48 hours. NOR-Normoxia, HYPO-Hypoxia. Adapted from Soni et al., submitted. 
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3.3.1 PERK-mediated secretion of proteins in glioblastoma 
To understand how PERK might regulate angiogenesis under low oxygen concentration in glioblastoma, 
we aimed to identify extracellular matrix proteins which are induced by hypoxia activated PERK. In that 
respect, LN308 glioblastoma cells were cultivated and treated with GSK2606414 (1 µM), a PERK 
inhibitor, under normoxic or hypoxic conditions for 72 hours. Proteomics analysis of the conditioned 
media was performed to identify secreted proteins that are regulated by PERK under hypoxia (Figure 16). 
Among the identified hits (Table 2), PAM was the only known protein to have its luminal domains secreted 
outside the cell. Its monooxygenase domains regulate the final step of the activation of neuropeptides for 
example, ADM, a known angiogenic protein. As PAM addresses both aspects of our study which are 
secretion of potential hit outside of the cell, as well as ability to regulate neo-blood vessel formation, we 
chose PAM for further validation and characterization of its involvement in PERK-mediated induction of 
angiogenesis in glioblastoma.  
 
 
Figure 16. Volcano plot representing the regulated secretory proteins from LN308 glioblastoma cells under 
hypoxic conditions for 72 hours without (left) and with GSK2606414 (right). 
The data are represented as the mean of three independent replicates. The significant P-value cut-off was set at 
0.05. Adapted from Soni et al., submitted. 
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Table 2. List of proteins found to be significantly regulated by PERK under hypoxia.  
 
 
 
Adapted from Soni et al., submitted. 
 
3.3.2 PERK regulates PAM independent of PERK kinase activity 
 In order to verify the involvement of PERK in the regulation of PAM in glioblastoma and thereby 
validating the mass spectrometry data, we harvested conditioned media from LN308 and LN229 cells 
upon PERK knockdown in hypoxic condition and determined the expression levels of PAM. PAM 
expression (both mRNA & protein) and secretion increased after 24 or 48 hours under hypoxia and 
strongly decreased upon silencing of PERK (Figure 17A-D). The results were confirmed in a low-passage 
patient-derived glioblastoma primary cell line (NCH82; Figure 17E). The PERK-mediated reduction of 
PAM protein was also verified by targeting PERK using a second shRNA in LN308 glioblastoma cells 
(Figure 17F). Next, we investigated whether PERK kinase activity is necessary for regulating PAM 
expression by comparing the effect of GSK2606414 (PERK kinase inhibitor) with PERK silencing. While 
PERK knockdown caused a significant decrease in PAM mRNA and protein levels in LN308 and LN229 
cells (Figure 17B and D), its kinase inhibition did not show any effect on PAM mRNA levels (Figure 17G) 
or an insignificant reduction on protein level (Figure 17H and I), suggesting that PERK-mediated 
regulation of PAM is independent of the kinase activity of PERK in glioblastoma.  
 
Accession Description 
Fold change 
GSK 
samples 
DMSO 
samples 
P19021 Peptidyl-glycine alpha-amidating monooxygenase (AMD_HUMAN) 1.83 2.26 
P19367 Hexokinase-1 (HXK1_HUMAN) 1.85 2.17 
Q05519 Serine/arginine-rich splicing factor 11 (SRS11_HUMAN) 1.43 2.16 
Q15811 Intersectin-1 (ITSN1_HUMAN) 1.95 2.61 
Q16666 Gamma-interferon-inducible protein 16 (IF16_HUMAN) 1.97 2.08 
Q9NQR4 Omega-amidase NIT2 (NIT2_HUMAN) 1.71 2.19 
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Figure 17. PERK regulates PAM at mRNA level independent of PERK kinase activity. 
PAM proteins levels in cells and conditioned media (precipitated using 10% TCA protocol) of LN308 (protein (A) and 
mRNA (B; single biological replicate)) and LN229 (protein (C) and mRNA (D; mean of five independent replicates ± 
SEM; t-test with *p-value < 0.05)) glioblastoma cells having either shNT or shPERK. Equal amount of protein was 
loaded from both the cells and the harvested conditioned media. EEF2 was used as a loading control of proteins 
isolated from cells whereas coomassie staining was used as a loading control for proteins isolated from conditioned 
media. RPS13 was used as housekeeper for RT-PCR. Cells were cultured in serum-free conditions. E) Expression of 
PAM under PERK knockdown in NCH82 low passage patient derived glioblastoma cells under hypoxia for 48 hours. 
F) Expression of PAM protein under PERK knockdown in LN308 glioblastoma cells under 24 hours of hypoxia using 
shPERK-2. G) PAM mRNA levels under PERK kinase inhibitor GSK2606414 in LN308 glioblastoma cells treated with 
hypoxia for 24 hours. The data is a representation of three independent replicates ± SEM; n.s.: not significant). 
RPS13 was used as housekeeper. H) PAM protein levels in LN308 under PERK inhibition using 500 nM 
GSK2606414. I) PAM protein levels under PERK inhibition using GSK2606414 (500 nM) in LN229 cells under 
hypoxia for 24 hours. NOR-Normoxia, HYPO-Hypoxia. Adapted from Soni et al., submitted. 
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PAM consists of to two enzymatic subunits i.e., PHM and PAL, which together amidates neuropeptides at 
the c-terminus and activates them for regulating different function in the microenvironment. In order to 
determine whether PERK also affects the activity of PAM, we measured the hydroxylating activity of PAM 
hydroxylating monooxygenase domain (PHM), which decreased upon PERK knockdown (Figure 18A and 
B). This supports the fact that PERK regulates the expression of PAM mRNA thereby also affecting the 
PHM activity of the glioblastoma.  
 
Figure 18. PERK regulates PAM activity under hypoxia. 
PHM activity in LN308 (A) and NCH82 (NCH82) cells (B) in hypoxia for 24 hours under PERK knockdown conditions. 
The data are represented as mean of three independent biological replicates ±SEM (t-test with p-value < 0.05* and < 
0.01**). NOR-Normoxia, HYPO-Hypoxia. Adapted from Soni et al., submitted. 
 
3.3.3 PERK is the only eIF2α kinase affecting expression of PAM in glioblastoma 
Our previous observations of hypoxia-mediated increase in phosphorylation of eIF2α and expression of 
PAM mRNA in glioblastoma cells raised two distinct questions. We asked whether PERK regulates the 
phosphorylation of eIF2α under hypoxic condition in LN229 glioblastoma cells and whether other eIF2α 
kinases can also regulate expression of PAM mRNA (Figure 14B). To determine whether increase in 
PAM mRNA is dependent solely on PERK and whether eIF2α phosphorylation also plays any role in PAM 
regulation, we knockdown all eIF2α kinases in LN229 cells and checked for PAM expression under 
hypoxia. Figure 19A shows prominent reduction of PAM protein with PERK knockdown elucidating the 
importance of PERK for its expression. Surprisingly, knockdown of GCN2, PKR and HRI strongly 
increased the expression of PAM in LN229 glioblastoma cells at both mRNA and protein levels. This 
suggests a PERK specific increase of PAM mRNA in glioblastoma cells under hypoxia (Figure 19A-C). 
On the other hand, phosphorylation of eIF2α reduces only under HRI knockdown condition, which implies 
dependency of eIF2α phosphorylation on HRI kinase under hypoxia and not on PERK. This also 
overrules dependency of PAM expression on P-eIF2α levels. Thus, in accordance with these results, the 
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PERK is suggested to be the only eIF2α kinase increasing PAM mRNA expression in glioblastoma under 
hypoxic condition.  
 
Figure 19. PERK is the only eIF2α kinase affecting expression of PAM in glioblastoma under hypoxia. 
PAM protein (A) and (B) mRNA levels under knockdown of PERK, GCN2, PKR and HRI in LN229 cells when treated 
with hypoxia for 24 hours. The mRNA expression data is normalized to shNT normoxia control and is represented as 
mean of one biological replicate. RPS13 was used as a housekeeper. C) mRNA fold change of individual eIF2α 
kinases under knockdown condition normalized to non-target control. NOR-Normoxia, HYPO-Hypoxia. 
PERK is also known to show its kinase activity towards NRF2 thereby inducing its nuclear localization. 
This active NRF2 binds to antioxidant response elements (ARE) on the promoter region of stress and 
antioxidant genes leading to their expression. As PERK knockdown reduced the PAM mRNA level, we 
determined whether PERK regulates PAM mRNA expression via NRF2. LN229 cells treated with tBHQ, a 
selective activator of NRF2 showed increase in NRF2 target genes like NQO-1 and HO-1 whereas no 
increase was observed in PAM mRNA expression under these conditions (Figure 20A). In the same 
direction, we observed no changes in PAM mRNA expression under hypoxia treatment when NRF2 was 
knocked down in LN229 glioblastoma cells depicting no role of NRF2 in regulating PAM mRNA 
expression (Figure 20B). These observations also supports the fact that PERK kinase activity does not 
regulate PAM mRNA expression in glioblastoma. 
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Figure 20. PAM mRNA increase under hypoxia is NRF2-independent. 
A) PAM mRNA expression in LN229 cells under NRF2 activation using tBHQ. NQO-1 and HO-1 were used as 
positive controls for tBHQ-mediated activation of NRF2 target genes. RPS13 was used as housekeeping gene. Data 
are normalized to the untreated control and is represented as single biological replicate. B) PAM mRNA expression in 
LN229 cells under NRF2 knockdown. The experiment was performed as single biological replicate. RPS13 was used 
as housekeeping gene.  
  
3.3.4 PERK kinase activity is essential to generate PAM sfCD domain possibly via a 
physical interaction 
As PERK kinase activity does not seem to be necessary for the regulation of PAM at the mRNA level, we 
asked ourselves whether active PERK is involved in the post-translational modification of PAM. PAM is 
composed of several domains which also include the unstructured cytosolic domain that can be cleaved 
to generate sfCD (soluble fragment-cytosolic domain). PAM sfCD has been previously shown to be 
localized to the nuclei and suggested to be involved in the regulation of gene expression. LN229 cells 
with PAM over-expression or knockdown were treated with PERK activator CCT020312 under hypoxia. 
Interestingly, we observed an increased amount of the 16 kDa PAM sfCD (Figure 21A), a phenomenon 
that occurs in a concentration dependent manner and happens independently of the oxygen level (Figure 
21B and C). Indeed, we found a reduction in PAM sfCD when hypoxia-activated PERK was inhibited 
using GSK2606414 in LN229 cells (Figure 21D) which strongly supports that the activity of CCT020312 
towards PAM sfCD was PERK-specific.  Our data highlight the importance of PERK kinase activity in 
regulating the generation of PAM sfCD without inducing any changes at PAM mRNA level (Figure 21E).   
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Figure 21. PERK activation causes accumulation of the PAM sfCD fragment, possibly via a physical 
interaction. 
A) sfCD PAM levels in LN229 cells with PAM knockdown or with PAM overexpression treated with 4 μM CCT020312 
under 24 hour hypoxia. Plasmid overexpressing turboGFP (tGFP) was used as negative control. sfCD PAM levels in 
LN229 cells having either PAM overexpression (B) or knockdown (C) were treated with different concentrations of 
CCT020312 under normal oxygen concentration. Plasmid overexpressing turboGFP (tGFP) was used as negative 
control. D) PAM sfCD levels under hypoxia with and without inhibition of PERK kinase activity using GSK2606414 in 
LN229 cells under 24 hours of hypoxia. E) PAM mRNA levels from LN229 cells treated with 4 μM of CCT020312 
under hypoxia. Data were normalized to the housekeeper RPS13 and are represented as the mean of three 
independent experiments ± SEM (t-test with n.s.: not significant). F) PAM and PERK immunofluorescence images 
from LN308 cells treated with hypoxia for 24 hours. DAPI was used as nuclear stain. Scale bars: 10 μm. G) Levels of 
PAM and PERK in co-IP experiments using respective antibodies in LN308 cells. H) PAM co-IP with PERK antibody 
from HEK293 cells over-expressing PAM protein. NOR-Normoxia, HYPO-Hypoxia. Adapted from Soni et al., 
submitted. 
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As both proteins localize to the cytoplasm (Figure 21F), we determined whether PERK interacts with PAM 
by co-immunoprecipitation in LN308 cells as well as in HEK293 cells over-expressing PAM (Figure 21G 
and H). The data indicate that the proteins bind to each other which might be important for the generation 
of PAM sfCD. The fact that PERK interacts with PAM and regulates the generation of PAM sfCD led us to 
ask whether PERK can also phosphorylate PAM protein. PAM cytosolic domain consists of multiple 
phosphorylation sites of which two most studied residues, serine 937 and serine 949 are shown to 
regulate its trafficking through endocytic pathway. To address the same question and determine whether 
PERK can phosphorylate PAM at Ser937 and Ser949, we treated the LN229 cells with CCT020312 (4 
µM) for 24 hours and immunoprecipitated PAM protein. To analyze P-Ser937 and P-Ser949 PAM 
populations, we used phospho-specific antibodies. Figure 22 shows no significant increase in any of the 
phosphorylation states of PAM or PAM sfCD when treated with CCT020312 suggesting that PERK does 
not phosphorylate PAM and thus there might be a possible indirect regulation of PAM sfCD by PERK 
kinase domain.  
 
Figure 22. PERK does not phosphorylate PAM at Serine 937 and Serine 949 residue. 
Levels of P-Ser937 and P-Ser949 in LN229 cells treated with/without CCT020312 (4µM) for 24 hours under hypoxia 
observed after immunoprecipitating total PAM protein. 
 
3.3.5 PERK and HIF1α regulates expression of PAM via AP-1 transcription factor 
Hypoxia regulates the expression of PAM in different glioblastoma cell lines both at mRNA (Figure 23A) 
and protein levels (Figure 23B-D) which also affects its PHM activity and secretion (Figure 23E-F). As 
PAM has also been identified in purified exosomes, we prepared a crude extracellular fraction from the 
conditioned media of LN308 cells treated with hypoxia and observed the expression of PAM by immuno-
electron microscopy (Figure 24A and B). Next, we determined whether Hypoxia inducible factor 1α 
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(HIF1α) was responsible for the increased level of PAM expression under hypoxia. LN308 cells were 
transduced with shNT or shHIF1α and cultivated under low oxygen conditions. HIF1α knockdown 
significantly reduced the level of PAM at mRNA and protein level. Taken together, the data demonstrates 
that HIF1α stabilization is required for PAM mRNA increase under hypoxia in glioblastoma (Figure 25A 
and B). 
 
 
Figure 23. PAM mRNA increases under hypoxia in glioblastoma. 
A) PAM mRNA levels under hypoxia in different glioblastoma cell lines. EEF2 was used as housekeeping gene. Data 
are normalized to the respective normoxic conditions and are represented as the mean of three independent 
biological experiments ± SEM (t-test: p-value < 0.05* and< 0.01**). B) Time course increase in expression of PAM in 
LN308 glioblastoma cell line. C) Expression of PAM under hypoxic conditions in LN229 and human astrocytes (NHA). 
D) PAM protein levels under CoCl2 treatment in LN308 cells. E) PHM activity in different glioblastoma cell lines under 
24 hours of hypoxia. The experiments were performed in three independent biological replicates ± SEM (t-test: p-
value < 0.05* and < 0.001***). F) Secretion of PAM protein in conditioned media from LN308 and NCH82 cells. NOR-
Normoxia, HYPO-Hypoxia. Adapted from Soni et al., submitted. 
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Figure 24. PAM is also secreted in extracellular vesicles from 
LN308 glioblastoma cells under hypoxia. 
Vesicles isolated from the conditioned media of LN308 cells 
treated with 24 hours of hypoxia using sequential centrifugation 
method. Vesicles stained with immuno-labeled gold (Au) particle 
are used to detect PAM (A) and CD63 (B), an exosomal marker 
from cells with either shNT or shPAM. Red arrow indicates Au-
label. Scale bars: 100 nm. Adapted from Soni et al., submitted. 
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Figure 25. PAM mRNA increase under hypoxia is HIF1α dependent. 
mRNA (A) (mean of three independent biological replicates ± SEM; t-test with p-value < 0.05* and < 0.001***) and 
protein (B) levels of PAM under non-target or HIF1α knockdown in LN308 cells. RPS13 was used as housekeeping 
gene. NOR-Normoxia, HYPO-Hypoxia. Adapted from Soni et al., submitted. 
 
3.3.6 In silico transcription binding affinity (TBA)-based prediction of potential 
transcription factors regulating PAM mRNA expression 
As PERK and HIF1α both regulates PAM mRNA levels we took an in silico approach in order to identify 
potential transcription factors (TFs) of PAM that might be regulated by PERK. We performed comparative 
analysis of transcription binding affinities (TBAs) of all TFs and generated a list with TFs having the 
highest TBAs for the PAM promoter (NM_138821) defined as -1500 bases to +500 base pairs from the 
transcription start site (Table 3). From the putative transcription factors identified, several members of the 
AP-1 transcription complex such as FOSL1, JUND and JUNB were among the top hits (Figure 26A-C).  
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Table 3. Log2- and z-transformed TBAs, for 579 TF binding motifs from JASPAR, for the promoter of PAM 
transcripts (NM_138821). 
Only motifs with scores >= 1.5 are reported. Adapted  from Soni et al., submitted. 
 
ID Name z-Score 
MA0665.1 MSC 2.68 
MA0784.1 POU1F1 2.42 
MA0787.1 POU3F2 2.36 
MA0786.1 POU3F1 2.27 
MA0866.1 SOX21 2.21 
MA0735.1 GLIS1 2.10 
MA0737.1 GLIS3 2.03 
MA0795.1 SMAD3 2.01 
MA0667.1 MYF6 2.01 
MA0031.1 FOXD1 1.82 
MA0157.2 FOXO3 1.81 
MA0080.4 SPI1 1.80 
MA0845.1 FOXB1 1.77 
MA0785.1 POU2F1 1.73 
MA0842.1 NRL 1.72 
MA1103.1 FOXK2 1.70 
MA1152.1 SOX15 1.67 
MA0032.2 FOXC1 1.63 
MA0788.1 POU3F3 1.61 
MA0852.2 FOXK1 1.61 
MA0089.1 MAFG::NFE2L1 1.60 
MA0751.1 ZIC4 1.57 
MA1137.1 FOSL1::JUNB 1.57 
MA0789.1 POU3F4 1.55 
MA1128.1 FOSL1::JUN 1.55 
MA1141.1 FOS::JUND 1.54 
MA0792.1 POU5F1B 1.52 
MA0613.1 FOXG1 1.51 
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Figure 26. Total binding affinities of the PAM 
promoter. 
 A) Distribution of log2- and z transformed TBAs of all 
579 TF binding motifs on the promoter of PAM 
transcripts NM_138821.The red line indicates a z-score 
of 1.5 indicating a log2-transformed TBA of half a 
standard deviation above the average. Distribution of 
log2- and z-transformed TBAs of FOSL1::JUN (B) and 
FOSL1::JUNB (C) for the 25,387 promoters. The red 
vertical line indicates the z-score of both the 
transcription complex pair obtained for the PAM 
promoter. Adapted from Soni et al., submitted. 
 
 
3.3.7 Differential expression of PAM in glioblastoma subtypes and its relation to AP-1 
transcription factor. 
In order to determine whether AP-1 regulates the increase of PAM mRNA in glioblastoma, we inhibited 
AP-1 in LN308 cells using the specific inhibitor SR11302 (AP-1i) under hypoxia. The AP-1i reduced PAM 
mRNA levels suggesting a putative role of AP-1 in driving PAM expression (Figure 27A). Gene 
expression-based molecular classification has divided glioblastoma into three main subtypes namely, 
classical (CL), proneural (PN) and mesenchymal (MS). To find out whether PAM expression is 
glioblastoma subtype-specific, we checked PAM mRNA and protein levels in mesenchymal-subtype 
glioma-stem like cells (GSCs; NCH705 & NCH711) and pro-neural GSCs (NCH644 and NCH421K) under 
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hypoxia (Figure 27B and C). Surprisingly, PAM expression was found only in mesenchymal subtype 
GSCs at both protein and mRNA levels.  
 
 
 
Figure 27. Differential expression of PAM in glioblastoma subtypes and its relation to AP-1 transcription 
factor. 
A) PAM mRNA regulation in the presence of AP-1i (SR11302) in LN308 cells under 24 hours of hypoxia. The data is 
represented as a mean of two independent biological replicates. PAM protein (B) and mRNA (C) levels in 
glioblastoma subtypes when treated with hypoxia for 72 hours. The data is represented as single biological replicate. 
mRNA levels are normalized to normoxic NCH705. RPS13 was used as housekeeper. Box plot showing the 
expression levels of PAM (D) and FOSL1 (E) mRNA in glioblastoma patients classified into different subtypes (data 
retrieved from https://www.cancer.gov/tcga; error bars depict standard deviation in the expression values (t-test with 
p-value <0.001***)). F) mRNA fold change in expression of target genes under HIF1α and FOSL1 knockdown in 
NCH705 GSCs. RPS13 was used as housekeeper. The data is representation of a single biological replicate. 
Knockdown efficiency of (G) HIF1α and (H) FOSL1 for the experiment in (F). RPS13 was used as housekeeper. N-
Normoxia, H-Hypoxia. Adapted from Soni et al., submitted. 
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Mesenchymal GSCs also showed increased expression of AP-1 components FOSL1 and c-JUN 
supporting the involvement of AP-1 transcription factor in regulating the expression of PAM mRNA. 
Clinical data also shows a high expression of PAM and FOSL1 mRNA in mesenchymal subtype of 
glioblastoma (Figure 27D and E)
233
. Furthermore, knocking down both HIF1α and FOSL1 reduced PAM 
mRNA levels in NCH705 GSCs confirming the previous finding that FOSL1 mediates the expression of 
PAM in glioblastoma (Figure 27F-H). In that respect, the AP-1 complex, particularly FOSL1, seems to be 
an important transcription factor in the regulation of PAM expression in glioblastoma. Although, whether 
PERK regulates PAM mRNA expression in glioblastoma via AP-1 is still a question to be answered. 
 
3.3.8 PAM regulates angiogenesis in vitro 
PAM monooxygenase activity is the rate-limiting step for the activation of several neuropeptides like 
oxytocin, vasopressin and adrenomedullin (ADM). As ADM is a known for its role in regulating 
angiogenesis, we wanted to observe whether PAM also plays a pro-angiogenic role in glioblastoma. The 
two ways with which we could have checked the contribution of PAM towards angiogenesis was either by 
inhibiting its activity with known inhibitor 4P3BA or knocking down its expression using shRNA. We first 
opted to examine the effect of 4P3BA on the expression and activity of PAM. For this, we treated LN308 
cells with 4P3BA and observed only a slight reduction in the PHM activity (Figure 28A). On the other 
hand, 4P3BA enhanced PAM expression in LN308 cells which might be the reason of a positive feedback 
mechanism thereby showing little effect of 4P3BA on PHM activity of the cells (Figure 28B). As the 
inhibition of PHM activity of the cells by 4P3BA was not strong, we decided to check the effect of PAM on 
angiogenesis by reducing its expression using shRNA-mediated knockdown.  
 
Figure 28. 4P3BA does not effectively reduce PHM activity in LN308 glioblastoma cells. 
PAM PHM activity (A) and protein levels (B) in LN308 cells under hypoxia with PAM inhibitor 4P3BA. NOR-Normoxia, 
HYPO-Hypoxia. 
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We performed the standard tube formation assay where we subjected HUVECs with conditioned media 
from non-target and PERK or PAM knockdown LN229 cells treated under hypoxia and allowed them to 
form tubes on growth factor-reduced matrigel within 24 hours. The number of junctions and tube meshes 
formed by HUVECs significantly decreased when nourished with conditioned media from shPERK and 
shPAM LN229 cells in comparison to non-target control (Figure 29A and B). 
 
Figure 29. PERK and PAM support blood vessel formation in glioblastoma in vitro. 
A) Tubes formed by HUVECs when treated with conditioned media from PERK and PAM knockdown LN229 cells 
along with non-target control. Scale bars: 500 μm. B) Plots showing number of junctions and meshes formed by 
HUVECs when treated with conditioned media from shPERK and shPAM LN229 cells. The data is normalized to the 
shNT control and is represented as a mean of three independent biological replicates ± SEM (t-test with p-value < 
0.05*, <0.01** and < 0.001***). C) ADM mRNA expression in LN308 and LN229 glioblastoma cells. The data is 
represented as a single biological replicate. EEF2 was used as housekeeper. NOR-Normoxia, HYPO-Hypoxia. 
Adapted from Soni et al., submitted. 
 
We also confirmed the expression of ADM mRNA in LN308 and LN229 cells (Figure 29C) and observed 
an increase in the number of junctions and tube meshes formed by HUVECs when treated with active-
ADM (ADM-NH2; Figure 30A and B). Thus, in light of these results we propose a pro-angiogenic role of 
PAM in glioblastoma. 
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Figure 30. Active ADM increases number of junctions and meshes formed by HUVECs in vitro. 
A) Images showing tubes formed by HUVECs over reduced-matrigel for 18 hours in the presence of different 
concentrations of active adrenomedullin active. The data are represented as mean of three technical replicates. Scale 
bars: 1000 µm. B) Corresponding numbers of junctions and meshes formed by HUVECs under adrenomedullin 
treatment. Adapted from Soni et al., submitted. 
 
3.3.9 PAM regulates tumor progression in vivo. 
Literature evidence shows that PERK expression affects the tumor growth kinetics. To observe the same 
and determine whether PAM reduction can also affect glioblastoma proliferation, we knockdown PAM and 
PERK using shRNA and analyzed cell proliferation in glioblastoma cells. The data (Figure 31A and B) 
suggests more than 50% reduction in the viability of LN229 cells upon PERK knockdown whereas no 
effect of PAM knockdown was observed on proliferation of LN229 cells. As PERK knockdown would have 
completely reduced the chances of tumor engraftment in vivo, we planned to not go further with analyzing 
the effect of PERK knockdown but rather observe the effect of PAM knockdown on tumor growth kinetics. 
To determine the effect of PAM knockdown on glioblastoma progression and overall survival of mice, we 
implanted LN229 cells expressing GFP-2A-luciferase in immuno-compromised NSG mice and recorded 
total flux (photons/sec) 7 and 14 days after implantation. Reduced PAM expression decreases tumor 
growth kinetics and increased the overall survival in the glioblastoma model (Figure 31C-E). Interestingly 
PAM mRNA expression is also increased in glioblastoma patients as compared to normal brain and high 
expression correlates with poor prognosis (Figure 31F and G). Altogether, we propose that PAM 
expression supports the growth of glioblastoma in vivo and acts as one of the important factor responsible 
for poor prognosis in glioblastoma patients. 
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Figure 31. PAM expression is necessary for progression of glioblastoma in vivo. 
A) Cell Titer-Glo® luminescent cell viability assay showing the effect of PERK on LN229 cell viability determined 3, 4, 
and 5 days post virus infection. The values correspond to the three biological replicates normalized to the respective 
shNT control ± SEM (t-test with p-value < 0.05*, <0.01** and < 0.001***). B) Cell Titer-Glo® luminescent cell viability 
assay showing the effect of PAM on LN229 cell viability determined 3, 4, and 5 days post virus infection. The values 
correspond to the two biological replicates normalized to the respective shNT control. C) Tumor growth kinetics on 
the basis of total flux calculated for mice implanted with LN229 cells having either shNT or shPAM for the indicated 
time-points. The data is normalized to respective shNT control and contains 12 mice per cohort ± SD (t-test with p-
value < 0.05*, <0.01** and < 0.001***). D) Representative bio-luminescence images of mice 14 days after 
implantation with LN229 glioma having expression of either shNT or shPAM for the indicated time-points. E) Overall 
survival of mice with shNT and shPAM LN229 glioblastoma using Kaplan Meier survival analysis. Significance was 
calculated using Log-rank method. F) Scatter dot plot showing the expression levels of PAM in glioblastoma patients 
versus the normal brain control (data retrieved from Gravendeel et al. 2009; error bars depict standard deviation in 
the expression values (t-test with p-value <0.01**)). G) Kaplan Meier survival analysis representing percentage 
survival of patients with low (green) and high (red) PAM expression from Gravendeel et al. 2009. Most significant 
expression cutoff was used for survival analysis. Significance was calculated using Log-rank method. Adapted from 
Soni et al., submitted. 
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4. Discussion 
(The text in this section has been adapted from Soni et al., submitted, which corresponds to my PhD 
research project.) 
PERK has been previously showed to sustain tumor growth by regulating the expression of angiogenic 
factors like VEGF which in turn provides nutrients and oxygen to proliferating cancer cells. Many studies 
have reported the activation of UPR under stressful hypoxic condition in order to enhance their 
survival
234–237
. Targeting VEGF using the monoclonal antibody Bevacizumab has shown variable clinical 
outcomes with respect to the type of cancer, wherein patients with metastatic colorectal cancer and non-
small cell lung cancer has seen significant increase in overall survival (OS) but patients with metastatic 
breast cancer and glioblastoma have shown improvement of the progression-free survival (PFS) rate
238–
241
. The reasons behind the unfavorable outcome from these clinical trials may include insensitivity of anti-
VEGF therapy towards tumor blood vessel
242
, alternative angiogenic growth factor expression
243,244
, 
increased recruitment of myeloid cells supporting tumor angiogenesis
245,246
, pericytes-mediated protection 
of endothelial cells and therapy-induced mesenchymal phenotype of tumor cells
247,248
. As current 
angiogenic therapies have failed to provide any benefit to the glioblastoma patients, there is an urgent 
need to identify other angiogenic factors in glioblastoma and possibly the mechanism behind their 
expression to effectively target them. Here, we aimed to determine which secretory factors might be 
responsible in mediating PERK-induced angiogenesis in glioblastoma. We conducted a mass 
spectrometry screening of the secretome of LN308 glioblastoma cell line under hypoxic stress and 
identified PAM to be regulated by PERK under these conditions. We found a HIF1α-dependent increase 
of PAM mRNA expression under hypoxia. We also provide evidence of a transcription-independent 
regulation of PAM sfCD under the influence of active PERK which might be an effect of formation of a 
complex between PERK and PAM. Our in vitro study confirmed PAM-mediated induction of tube 
formation by HUVECs whereas our in vivo data suggests PAM-led progression of glioblastoma in 
xenograft mice. 
Initially, we characterized UPR pathway in glioblastoma cells and analyzed whether these cells are better 
adapted to endoplasmic reticulum (ER) stress condition in comparison to a non-glioblastoma cell model 
(HEK293). IRE1α is a dual activity protein that maintains cellular proteostasis. Upon sensing miss-folded 
proteins in the lumen of the ER, IRE1α gets dimerized and auto-phosphorylates its kinase domain thereby 
activating it’s RNase activity
249,250
. It’s RNase domain-mediated generation of XBP1s acts as a pro-
survival factor for tumor growth whereas it’s RIDD activity has been found responsible for regulating the 
expression of different invasive and angiogenic factors for example SPARC, CTGF, etc
251–253
. However, 
prolonged ER stress leads to IRE1α-mediated activation of apoptosis via IRE1α kinase-JNK-ASK1 
pathway
254
. To avoid such situations during the initial phase of ER stress, UPR activation also leads to 
the generation of a negative feedback loop. PP2A and PPM are the two phosphatases which 
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dephosphorylate and thus inactivate IRE1α
65,255
. Stimulation of UPR by tunicamycin, an ER stress 
inducer, led to the phosphorylation of IRE1α at Ser724 residue in LN308 glioblastoma cells. The 
treatment also activated IRE1α and generated XBP1s in both glioblastoma cells as well as HEK293, 
however glioblastoma cells were found to have a better adaptation to chronic ER stress condition as 
observed by a reduced amount of XBP1s generation during second cycle (24 hours) of IRE1α RNase 
activity. This difference between glioblastoma and HEK cells could be due to differentially enhanced 
expression of factors responsible to maintain proteostasis for example, chaperons, etc, or high 
expression of proteins responsible for inhibition of IRE1α enzymatic activity, such as phosphatases. We 
also observed IRE1α-mediated regulation of invasive and angiogenic factors, like HEVIN, CYR61 and 
CTGF in LN308 glioblastoma cell lines. Inhibition of IRE1α endoribonuclease activity by STF083010 led 
to the stabilization of HEVIN and CTGF whereas IRE1α activation using APY29, an IRE1α-specific 
activator, led to reduction of their expression. PERK also gets dimerized and auto-phosphorylates itself 
upon accumulation of miss-folded protein within the ER and reduces overall translation of the cell by 
phosphorylating and inactivating eIF2α
256
. Phosphorylation of eIF2α leads to the disruption of the 
translation initiation complex which reduces the translation of regular proteins but enhances the 
expression of stress-induced proteins including ATF4 and CHOP
75
. Like, IRE1α, PERK activity can also 
be affected by a negative feedback loop where expression of GADD34 and PPP1R15B downstream of 
ATF4 leads to dephoshorylation of eIF2α thereby activating cellular translation machinery
78,257,258
. 
Treatment of LN308 glioblastoma cells with tunicamycin for 6 hours also led the activation of PERK 
branch of the UPR as could be observed by phosphorylation status of PERK, eIF2α and generation of 
ATF4. A reduction of P-elF2α and ATF4 expression after 16 hours of tunicamycin treatment was also 
observed which might have happened because of feedback inhibition by expression of GADD34 and 
PPP1R15B. 
Decades of research has shown involvement of UPR in tumor development although there is still little 
information known regarding branch-specific regulation of tumor development in glioblastoma
44,45,247
.By 
investigating the secretome of glioblastoma, we have identified a new function of the UPR sensor PERK 
mediating the expression and cleavage of PAM. The UPR plays a major role in cancer progression being 
involved in the activation or repression of oncogenes and tumor-suppressor genes such as 
BRAFv600E
149
 and H-RAS
151
, respectively, regulating proliferation and angiogenesis
154
, as well as 
invasion and tumor metastasis via the regulation of transcription factors such as SNAIL1, SNAIL2, ZEB2 
and TCF3
165
. Most importantly, the UPR is among the main mechanisms involved in the adaptation of 
glioblastoma to the hypoxic stress, inducing its aggressive phenotype
236,237
.When characterizing the 
activation of different UPR branches in low oxygen conditions, we found activation of PERK and ATF6α 
only, and a reduction in the activity of both domains of IRE1α. This could be a consequence of better 
adaptation of these cells to the hypoxic stress conditions avoiding the activation of pro-apoptotic 
mechanisms downstream of UPR signaling such as CHOP production or IRE1α-mediated activation of 
TRAF2-JNK-ASK1 signaling
66,259
. Unlike previous studies, our data suggest a selective activation of 
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different UPR branches under 1% O2 in glioblastoma, a phenomenon that could be explained by the 
different levels of oxygen to which the tumor cells are exposed in the different tissues.
260,261
 
Confrontation of cancer cells with both intrinsic metabolic burdens like nutrient deprivation, and 
simultaneous exposure to external environmental stresses including chemotherapeutic drugs, drives them 
towards activating the UPR in order to cope up with the increasing demand of protein synthesis. UPR 
thus, not just helps in maintaining protein homeostasis within the cell but also alerts the neighboring cells 
of the spawning tension in the microenvironment.
262–264
 External transfer of stress signaling by UPR has 
recently come out to be an important phenomenon to induce immunogenicity against cancer cells which 
is most significantly being driven by PERK by a phenomenon known as DAMPs (Damage Associated 
Molecular Patterns)
265
. However, literature suggests that this extrinsic signaling via UPR can activate both 
pro- or anti-tumor inflammatory respons.
266,267
 
As PERK is known to regulate the expression of several angiogenic factors such as VEGF-A, IL6 and 
FGF
236,268
, we aimed to identify secreted factors that might be involved in PERK-mediated angiogenesis 
in glioblastoma. By proteomic screening of the secretome of the LN308 glioblastoma cell line under 
hypoxic stress, we identified PAM to be regulated by PERK. Among the identified hits, PAM is the only 
protein known to be either present on the plasma membrane, exosomal vesicles or secreted out as a 
cleaved product
199
. In that respect, we concluded that expression of PAM is significantly increased with 
reduced oxygen levels in glioblastoma cell lines only and shows an important regulation by HIF1α at the 
transcriptional level. Our data also suggested the presence of PAM expression on crude exosomal 
fraction from glioblastoma cells treated with hypoxia. As exosomes have been suggested to be a major 
tool with which cancer cells communicate with their microenvironment, presence of PAM on glioblastoma 
exosomes also implies the importance of PAM for the aggressiveness of glioblastoma. PAM has been 
shown previously to induce cytoskeleton rearrangements as well as the production and secretion of 
neuro-peptides
269,270
. It is composed of several luminal domains, a transmembrane domain and an 
unstructured cytosolic domain (PAM-CD), which facilitates its ability to interact with different proteins. The 
multiple phosphorylation sites among the 86 amino acid residues in this unstructured domain determine 
endocytic trafficking and proteolytic cleavage of PAM and influence the generation of PAM soluble 
fragment cytosolic domain (sfCD)
271,272
. Like other membrane proteins, such as SREBP (Sterol-regulatory 
element-binding protein) or ICA512 (an autoantigen of type I diabetes), PAM sfCD was also shown to 
transfer signals to the nuclei as a feedback mechanism
273,274
. Indeed, gene expression profiling of AtT-20 
cells (mouse corticotrope tumor cells) overexpressing PAM showed increased expression of Aquaporin 1 
(Aqp1) and secretory leukocyte peptidase inhibitor (Slpi), affecting formation and proteome content of 
secretory granules
275–277
, both of which were validated to be regulated by PAM sfCD
209
. Moreover, Aqp1 
was also described to be involved in tumor migration, invasion and angiogenesis in glioblastoma
278,279
. By 
treating glioblastoma cells with a PERK activator, we show that its kinase activity is involved in the 
generation of the PAM sfCD, which might occur via a direct interaction between the proteins as 
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suggested by our findings. Recently published RNA-seq data showed many different pathways to be 
affected by PAM. Atf3, one of the major repressor transcription factor of UPR genes, was down-regulated 
upon PAM overexpression while Fkbp2, a peptidyl prolyl isomerases (PPIase) from FK506 binding 
proteins (FKBPs) family responsible for rate-limiting step in protein folding, was up-regulated highlighting 
the role of PAM in influencing ER protein folding capacity
280
. On the other hand, we were not able to 
observe any effect of PERK kinase activity on phosphorylation status of PAM suggesting an indirect effect 
of PERK kinase on generation of PAM sfCD. Our results, in the light of these studies, provide a strong 
hint towards the involvement of PAM in regulating essential pathways in glioblastoma including protein 
folding capacity of the ER, endocytic trafficking and secretion of factors necessary for tumor growth and 
angiogenesis.  
PERK reduces the ER stress by inhibiting protein translation and reducing oxidative stress. In order to do 
so, PERK phosphorylates eukaryotic initiation factor 2α (eIF2α) and NRF2, respectively
82,281
. Upstream 
open reading frames (uORFs) in the 5’ untranslated region (5’UTR) act as regulatory elements 
responsible for the inhibition of translation of the primary ORFs. In general, these regulatory uORFs are 
composed of short sequences and their translation lead to a frameshift which inhibits the translation of 
primary ORFs. Upon phosphorylation of eIF2α, the process of formation of translation initiation complex 
gets delayed which inhibits the translation of uORFs and lead to the expression of the primary ORF, for 
example, ATF4 expression. ATF4 regulates the transcription of many different mRNAs including 
chaperones responsible for the maintenance of protein homeostasis within the cell. ER stress can also be 
induced by other factors like amino acid deficiency, virus infection or reduced heme levels leading to the 
activation of GCN2, PKR or HRI, respectively, where these kinases also reduce the overall translation by 
phosphorylating eIF2α at serine-51 residue
282
. On the other hand, PERK-regulated stabilization of NRF2 
transcription factor leads to expression of anti-oxidative proteins like NQO-1, HO-1, etc
283,284
.  
Interestingly, although our data showed that PERK kinase activity has a major impact on PAM protein, 
only PERK silencing showed a very strong effect on PAM mRNA levels, a phenomenon that seemed to 
be HIF1α-dependent. Through our experiments we could also show that among all eIF2α kinases, PERK 
is the only kinase which can regulate the expression of PAM mRNA. Moreover, we could not find any 
significant role of NRF2 in regulating PAM mRNA expression downstream of PERK in glioblastoma. As 
PERK has also been previously shown to bear kinase-independent roles, for example, in attenuating 
mitochondrial oxidative stress by regulating the formation of MAMs (Mitochondrial associated 
membranes) at ER-mitochondria contact sites 
285
, we postulated that PAM regulation by PERK is another 
non-canonical kinase-independent signaling paradigm with which PERK regulates glioblastoma 
angiogenesis. 
Among the different glioblastoma subtypes, the mesenchymal (MES) one shows highly invasive growth, 
infiltration of microglia and thus poor prognosis of the glioblastoma patients
11
. NF1 loss of function and 
enhanced expression of AP-1 transcription factors are among the major genetic aberrations found in this 
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subtype of glioblastoma
11,286
. In silico analysis of the PAM promoter region revealed several putative 
transcription factors that might be involved in the regulation of PAM mRNA expression level, among 
which FOSL1, a component of the AP-1 complex. AP-1 consists of homo- or heterodimers of JUN and 
FOS family proteins and has been linked to EMT, invasion and metastasis in different cancer types 
including glioblastoma, and colorectal cancer, and has been found massively expressed in mesenchymal 
subtype of glioblastoma
287,288
. Moreover, HIF1α is an important regulator of AP-1, driving the nuclear 
localization of c-JUN
289
. Our data suggest that FOSL1-mediatedregulation of PAM mRNA expression as 
shown by AP-1 inhibition, under hypoxic conditions, might be due to an indirect effect of HIF1α 
stabilization. We found higher expression of PAM in MES-subtype of GSCs in comparison to the PN-
subtypes in vitro which is also supported by the clinical data provided by TCGA of subtype-stratified 
glioblastoma patients. However, how PERK regulates PAM mRNA levels still remains to be elucidated. 
PAM is a bi-functional type I membrane protein having a monooxygenase and lyase enzymatic units 
located on its luminal domains. Loss of PAM functionality has been implicated in various neuronal 
diseases, like, Menkes disease, multiple sclerosis and post-polio syndrome patients, thereby making it an 
important biomarker candidate 
290,291
. Several studies have also shown the importance of PAM in the 
activation of adrenomedullin (ADM), a neuro-peptide involved in angiogenesis and invasion, as well as in 
reducing pro-inflammatory phenotype of microglia
217,292,293
, and which occurred to induce tube formation 
in our glioblastoma cellular model. PAM homozygous knockout mice did not show any activation of ADM 
and die during embryogenesis due to severe edema, thinning of the aorta and carotid arteries depicting 
the importance of PAM in supporting ADM-mediated angiogenesis
294
.Our data highlighted the role of 
PERK and thereby PAM in regulating angiogenesis in glioblastoma. 
Aberrant angiogenesis is a fundamental process in tumor development and is partly responsible for the 
poor prognosis of glioblastoma patients. Although they have been targeted therapeutically, inhibition of 
angiogenic pathways in glioblastoma has only led to marginal success in reducing tumor burden. Indeed, 
Bevacizumab, a monoclonal antibody targeting the proangiogenic signaling molecule VEGFA, did not 
show promising results in glioblastoma, improving only the progression-free survival (PFS) in patients
241
. 
The reasons behind the outcome from these clinical trials may include insensitivity of anti-VEGF therapy 
towards tumor blood vessels
242
 and alternative angiogenic growth factor expression
243
, highlighting the 
importance identifying new angiogenic factors to be targeted. Determining the role of PERK in regulating 
PAM expression in xenograft mouse models would have been really challenging, as PERK knockdown 
reduced the survival of glioblastoma cells which might cause problems in engraftment of the tumor. On 
the other hand, recently published data shows that both PERK kinase inhibitors, GSK2606414 and 
GSK2656157 can inhibit RIPK1 with even higher efficacy thus providing misleading conclusions if used in 
in vivo
295
. Thus we chose to study only the effect of PAM expression on the growth of the tumor and 
survival of the mouse model. Silencing PAM in glioblastoma cells reduced tumor growth kinetics in vivo 
and thus increased overall survival of mice, demonstrating its importance for the tumor. Interestingly, 
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PAM mRNA expression level is significantly higher in glioblastoma patients as compared to normal brain 
samples and higher expression of PAM is an indicator of poor prognosis among glioblastoma patients
296
. 
Our study provides evidence of a new mechanism by which PERK regulates the expression and function 
of the proangiogenic factor PAM and highlights its potential to be considered as a therapeutic target for 
glioblastoma. 
 
 
Figure 32. PERK is necessary for the expression of PAM in glioblastoma. 
PERK (independent of its kinase activity) regulates the expression of PAM whereas its kinase activity mediates the 
generation of PAM sfCD. PAM can either be expressed on the plasma membrane or secreted out of the cells on 
exosomal membrane to induce microenvironment changes supporting tumor growth. TF, Transcription factor. 
 
Outlook 
The key objective of the PhD thesis was to investigate the involvement of UPR in glioblastoma secretome 
modulation under physiological hypoxic condition. In that respect, we opted for a proteomic approach and 
conducted mass spectrometry on the conditioned media of glioblastoma cell model. PAM was the most 
promising hit as it was known to be located on the membrane of exosomal vesicles and thereby acting as 
messenger influencing the tumor microenvironment. In order to uncover the regulatory role of PERK on 
PAM protein level, we characterized its involvement in PAM transcriptional and post-translational 
regulation, and studied its importance for tumor angiogenesis in vitro. PERK protein was found essential 
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for the expression of PAM mRNA level in glioblastoma under hypoxic condition, a phenomenon that was 
independent from its kinase activity, suggesting that a non-canonical signaling is responsible for this 
effect. The in silico TBA prediction provided a list of potentialtranscription factors binding to the PAM 
promoter region, particularly members of the AP-1 transcription complex such as FOSL1, FOS, c-JUN 
and JUNB. Interestingly, AP-1 inhibition reduced the level of PAM mRNA supporting the in silico 
prediction and suggesting an AP-1-mediated regulation ofPAM mRNA expression. As AP-1 transcription 
factor is known to be involved in tumor progression, it is crucial to verify the binding of the AP-1 complex 
to the PAM promoter region by using CHIP sequencing. 
Although PERK kinase activity was not regulating PAM at the mRNA level, our study confirmed the 
involvement of this enzymatic function for the generation of PAM sfCD, using the PERK selective 
activator CCT020312. In order to verify those results, we will overexpress a PERK kinase-dead mutant 
and investigate the level of PAM sfCD.   
Interestingly, previous studies have highlighted the role of PAM sfCD in regulating gene expression 
sustaining tumor progression. In order to address it in glioblastoma, the next step would be to perform 
gene expression profiling of glioblastoma cells treated with hypoxia, with or without PERK activator 
CCT020312. To ensure that the changes are specific to the sfCD domain, an additional control with PAM 
knockdown should be included. In addition, it will also be interesting to determine whether PAM sfCD 
directly regulates gene expression changes by binding to particular gene promoter regions or acts as a 
part of a transcription factor complex. 
Phenotypic characterization of PAM clearly highlighted its role in angiogenesis. This effect could be due 
to reduced ADM activation upon PAM knockdown, which could be verified by performing a HUVECs tube 
formation assay and determine whether administration of ADM-NH2 (active PAM product) can induce 
tube formation when treated with conditioned media from PAM knockdown glioblastoma cells.  
Our pre-clinical study suggests a prominent role of PAM in supporting tumor growth, as the silencing of 
PAM in orthotopically transplanted glioblastoma cells increased the overall survival of mice as compared 
to glioblastoma cells expressing endogenous PAM. The fact that PAM is not the only regulator of 
angiogenesis in glioblastoma and VEGFA, a well studied and therapeutically intervened angiogenic factor 
is also expressed in our glioblastoma model, there is a need to determine that the reduced angiogenesis 
leading to decrease in tumor growth is specifically because of PAM and ADM-NH2. This can be achieved 
by performing VEGFA immunohistochemistry on the tumor sections from the in vivo experiment and 
determine whether PAM knockdown changes VEGFA expression in the xenograft model. As PAM 
knockdown in LN229 cells did not reduce the growth of the tumor completely, further pre-clinical studies 
need to be performed in combination with current chemotherapeutics and observe whether a 
combinatorial therapy including PAM inhibitors can be used to drastically improve glioblastoma patient 
survival.  
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This will help us to further characterize the significance of PAM in glioblastoma and determine whether it 
can be used as a potential therapeutic target for clinical studies. PAM-specific small molecule inhibitor 
screen can be performed to identify drug that targets PAM activity and the identified hit can later be 
assessed for its clinical efficacy. The identified drug can also be analyzed for its usage in combination 
with other anti-angiogenic therapeutics for effectively targeting glioblastoma thereby reducing the tumor 
growth and increasing the prognosis of patients. 
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